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Abstract 
 Protein aggregation is a common occurrence when overexpressing protein in bacteria, it 
is also a hallmark of some neurodegenerative diseases such as amyotrophic lateral sclerosis 
(ALS). Mutations in the enzyme Cu, Zn- superoxide dismutase (SOD1) have been implicated in 
causing the familial form of ALS. Here, a number of SOD1 mutants expressed in E.coli are 
analysed for their propensities to aggregate in the form of inclusion bodies. The inclusion bodies 
are also analysed for their metal content of both Cu and Zn. The latter experiments were 
conducted both by a spectrophotometric assay using the metallochromic chelator 4-pyridylazo-
resorcinol and inductively coupled plasma atomic emission spectroscopy. 
 The SOD1 variants showed a large amount of variability in their propensities to 
aggregate and when compared to other physiochemical properties such as the thermal stability, 
there were clear trends, in particular between the aggregation propensity and the thermal stability 
of the reduced apo SOD1. In comparing the aggregation propensity to one aspect of the ALS 
phenotype, disease duration, there was no correlation. The metalation status of the SOD1 mutant 
inclusion bodies was found to be variable, even within repeated experiments with the same 
mutant. As metals are required for the enzymes activity, the metals present support the 
possibility that the inclusion bodies may retain activity. This may prove useful in the future if 
there is ever a need for an insoluble superoxide catalyst. The results of these experiments also 
further our understanding of SOD1 aggregation and metalation which may help future 
investigations in understanding ALS pathology. 
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1.0 Introduction 
1.1 General protein information 
1.1.1 Protein structure 
 
 Proteins are some of the most important components of life, they serve a wide array of 
functions without which, we as humans would not exist. A protein is a large biomolecule formed 
by a folded chain or multiple chains of amino acids. During the synthesis of the chain, even 
before it is released from the ribosome where it is being assembled, the protein may begin to fold 
through a process that is highly dependent on the energetic properties of the chain, the 
surrounding solvent, and other components such as chaperone proteins. The final structure of a 
protein defines its function, whether that be for structural support of a cell, molecular transport, 
or the catalysis of a chemical reaction. 
Generally, entropy favours a chain that is disordered, which means that the folds have to 
form structures that can overcome that energy. A hydrophobic collapse involving the 
coalescence of hydrophobic groups, expelling water from the core of the protein, is one of the 
first protein folding events to occur.  From this point, the protein does not have to undergo as 
many large changes in conformation to achieve its native structure, with a series of relatively 
complex motions leading to a more well-defined structure with the formation of extensive non-
covalent interactions1,2. There are a small number of common secondary structures that are 
observed in the folded form, including α-helices, β-sheets, β-turns, and loops3. The tertiary 
folding process may begin to occur at the same time as the secondary structure forming, with the 
combination of hydrophobic interactions, electrostatic forces, and in some cases the formation of 
disulfide bonds all involved in the folding  to the final native state2. 
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Many proteins are not limited to a single polypeptide chain, they may consist of multiple 
chains which, whether identical or different, may fold and associate with each other to form an 
oligomer. The proportion of proteins within an organism that are oligomeric is quite high, with 
approximately three quarters of the proteins in E.coli believed to be oligomers4,5.The protein of 
interest in the studies proposed here, Cu, Zn – Superoxide dismutase (SOD1) is a dimer of 2 
identical subunits6 and will be described in more detail in section 1.4.  
The environment in which a protein exists plays an important role in determining its 
structure. A cell is a very complex entity with diverse contents, many biomolecules within a cell 
require narrowly defined conditions to function. Much of the inside of a cell is the cytosol, the 
liquid filler of a cell, containing the molecules and ions required for the synthesis of 
biomolecules as well as the cells own architecture and function. Salts and other natural 
kosmotropic substances assist in keeping a protein folded after it has been synthesized. The cell 
also contains proteins which function solely to stabilize other proteins such as heat shock 
proteins, which can bind to another protein in times of stress or simply help a protein fold for the 
first time7–10.  
The process of folding within a cell entails molecular vibrations and rotations to form the 
most stable conformation possible for the given environment. It is an amazing feat to have a 
simple sequence of amino acids consistently form complex cellular machinery. The folding 
pathways that proteins take may be different from each other and there is still much to be 
discovered in this field8,11. 
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1.1.2 Function 
As mentioned above, proteins may have various functions, such as the structural support 
of a cell, the transport of materials into, out of, and throughout a cell, or a large number of 
catalytic roles. Many proteins utilize cofactors to assist in their purpose; these “extra” molecules 
can be organic, metallic, or a combination of both and can allow a protein to fill a very specific 
structural or functional role. Most enzymes are proteins and these can show great specificity in 
the reactions they catalyse. By using their complex structures, enzymes can not only catalyse a 
wide range of specific reactions, but each can catalyze their particular reaction with great 
effectiveness. In some cases an enzyme can increase the rate of a reaction to approximately 1015- 
1017 fold over its original speed12. When a cofactor is involved, the protein when bound to the 
cofactor is known as a holoenzyme, and without the cofactor is termed an apoenzyme3. The 
protein of interest here, SOD1, contains two metal cofactors, 1 Zn and 1 Cu per subunit; the Zn 
stabilizes the protein structure while the copper is involved in catalysis and is described in more 
detail in section 1.4.26. 
1.2 Protein aggregation 
1.2.1 Misfolding and formation of aggregates 
 The proper folding of a protein is an important factor with regards to its function and 
stability. Improper folding, when the protein does not conform to its native state, can induce 
changes in the level of function or even cause the complete loss of function. It can also affect the 
state of the proteins quaternary structure, possibly compromising a proteins ability to properly 
oligomerize. All of this may have a serious impact on an organism’s health in a variety of 
ways13. Environmental factors that may affect the folding process include some of those 
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mentioned in the previous section; temperature, pH, and the presence of the proper chaperones 
necessary for production. 
Aggregates may arise when specific hydrophobic regions of improperly folded or 
incompletely folded proteins interact with each other, or possibly also native like conformations 
of multiple proteins interact, similar to polymerization13. There are multiple forms of aggregates, 
such as amorphous aggregates, annular oligomers, fibrils, and inclusion bodies (IBs), some of 
which may have common intermediate structures. A stability diagram can be seen below in 
Figure 1.1 depicting the energy state of the protein through the folding and misfolding 
processes.14 
 
Figure 1.1: Stability diagram depicting the energy level of a protein in a given conformation 
during the processes of folding and/or aggregation. The protein progresses from an unstructured 
high energy state to a more energetically favorable compact state. The lowest energy states of a 
polypeptide are in the aggregate forms. Reprinted by permission from Macmillan Publishers Ltd: 
[Nature Structural and Molecular Biology]. Hartl, F. U.; Hayer-Hartl, M. Nat. Struct. Mol. Biol. 2009, 
16 (6), 574–581, copyright 2009.14 http://www.nature.com/nsmb/index.html 
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Amorphous aggregates tend to be large disordered clusters, while the other forms have 
some distinct structural features. For instance annular oligomers have a circular pattern of 
proteins while fibrils (including amyloid) have repeating units stacked upon one another, for 
instance the stacked β sheets of β amyloid15. Inclusion bodies, which are of importance in this 
particular study are one of the lesser understood forms of aggregates, the mechanisms of 
formation and the state of the contents have not been well defined. Some forms of aggregates are 
very stable, even more so than the native state.14 
 The aggregation of proteins has been linked to numerous diseases, including many 
neurodegenerative diseases such as: Parkinson’s, Alzheimer’s, Huntington’s disease, as well as 
amyotrophic lateral sclerosis (ALS).15–20 These connections between aggregation and disease 
have created a great interest in learning more about aggregation, a subject that was largely passed 
over previously.13 Aggregation is also of concern for industrial applications of proteins, since 
many recombinant proteins form IBs when over-expressed in bacteria. Utilizing this aggregation 
for purification purposes or understanding the factors that direct aggregation may prove useful 
for a wide range of proteins.21 
A large field of research is currently focused on developing methods to predict 
aggregation. Methods can be ab initio or empirical, with empirical methods incorporating 
information from experimental observations in the prediction algorithms. More specifically, 
Chiti and coworkers have pioneered empirically based methods for determining the relative 
aggregation propensity of a protein, including upon introducing mutations.22,23 Other algorithms 
have been developed such as the TANGO24 and Zyggregator25 algorithms which are also 
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empirically based methods that attempt to predict aggregation-prone regions or structures in a 
protein by incorporating experimental information. Alternatively, the Waltz method attempts to 
determine the aggregation prone regions of a protein simply based on a primary sequence.  
These methods have been improving and are beginning to show more accurate 
predictions in vitro, however, they are seemingly still inadequate for in vivo aggregation 
prediction and lack consistency between predictions for different proteins. Understanding protein 
folding both in vitro as well as in vivo is important; information regarding the aggregation of 
specific proteins in both environments can improve our knowledge of the general principles of 
folding and our ability to accurately predict protein aggregation. With regards to disease-linked 
aggregation, an accurate in vivo model would be valuable in accounting for the complex 
surroundings which include the interactions with chaperones and membranes, which an in vitro 
prediction cannot adequately accomplish. This supports experimental observations as an 
important method of determining if a protein will aggregate. The data from these experiments 
can be used to improve future protein aggregation prediction algorithms. 
1.2.2 Inclusion bodies 
There are various types of aggregates that are described using the term inclusion, 
however, this is not equivalent to the aggregates known as inclusion bodies. Inclusion bodies are 
one specific form of aggregate in which unfolded or misfolded protein will accumulate to high 
levels within a cell’s cytoplasm and are produced during over-expression in bacteria. The naming 
for aggregates seen in other organisms (e.g. Humans, mice) is less well defined and the SOD1 
aggregates found in humans described here will simply be referred to as inclusions, although 
other names such as “Lewy-body like” inclusions and hyaline inclusions have been used.26,27 
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Inclusion bodies can be very large (>10 μm in some cases28) and usually present like amorphous 
aggregates, as round with no immediately distinct structure. The IBs are commonly obtained by 
cell lysis followed by the washing with a gentle detergent such as Triton X-100 29 (Figure 1.2). 
  
 
 
Figure 1.2: Triton X-100 unit, a gentle non-ionic detergent commonly used in inclusion body 
preparations.  
 
 
The characteristics of inclusion bodies have been investigated by numerous groups, but 
there is still much debate regarding their structure and contents. Questions that have been studied 
include whether IBs are in fact amorphous or contain amyloid, however, the contents may vary 
depending on the protein30  and the conditions under which it was produced. The contents of 
aggregates are more well characterized in bacterial models (e.g. E.coli), with Garcia Fruitos et al. 
reporting up to between 90-95% of the inclusion bodies contents consisting of the over-
expressed protein.31,32 The initial understanding with respect to the structure was that IBs are for 
the most part structured amorphously, in a way unlike amyloid13,33, although, this is now in 
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contention, with studies from Wang et al. observing amyloid like properties of inclusion bodies 
formed by the secretory human bone morphogenetic protein-2.34 The reality may be that 
inclusion bodies do not conform to one defined structure. 
Inclusion body formation is generally believed to be concentration dependant, that is, 
when proteins are produced in large amounts, the cellular folding machinery is not sufficient to 
aid folding, leaving large amounts of unfolded or partially folded protein in close proximity.35 
Figure 1.3 depicts a number of possible parts that may compose or lead to an inclusion body. To 
support the mechanism of IB formation, there have been instances of ribosomal RNA and 
subunits of RNA polymerase identified from inclusions36, suggesting the protein may not be 
fully synthesized. Inclusion bodies are commonly found when over-expressing proteins that are 
not native to the host organism. The inclusions found in cases of disease, such as in ALS37, 
described further in section 1.2.2.2, are not as well characterized as those caused by over-
expression in bacteria, mainly due to the difficulty of working with low amounts of pathological 
aggregates from tissue.38 This is a major factor in determining how to study aggregation 
associated with ALS. Here we use E.coli as a model system, since SOD1 can be over-expressed 
to form IBs39 which can be characterized in various ways to define the determinants of 
aggregation in vivo. Knowledge acquired from the study of IBs can provide insights pertinent to 
the formation of ALS associated inclusions. 
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Figure 1.3: Routes of inclusion body formation. From synthesis by the ribosome (top), the 
initially unfolded polypeptide may attain various levels of structure such as being partially folded 
or oligomerizing before being incorporated into an inclusion body. Reprinted from Trends in 
Biochemical Sciences, 34/8, de Groot et al. Amyloids in bacterial inclusion bodies, 408-416, 
copyright 2009, with permission from Elsevier.33 
http://www.sciencedirect.com/science/article/pii/S0968000409001236 
 
In more specific examples of previous studies, inclusion bodies have been detected, 
quantified, and characterized using a wide variety of methods, including but not restricted to: 
immunoblots (western blots), electron microscopy, atomic force microscopy (AFM), Fourier 
transform infrared spectroscopy (FTIR), circular dichroism, x-ray diffraction, and fluorescence 
spectroscopy when reacted with specific dye compounds (Congo red, Thioflavin t etc.) or bound 
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to fluorescent tags (GFP or YFP)28,31,33,34,40–42 yet, more analysis is undoubtedly necessary for 
multiple purposes. 
1.2.2.1 Inclusion bodies in industrial applications 
Inclusion bodies are of particular interest in nanobiotechnology. They are a common 
occurrence when overexpressing heterogeneous proteins in bacterial cultures. Certain 
characteristics of bacterial inclusion bodies have made them more interesting to researchers 
recently. These characteristics include that their deposition is usually fully reversible and a 
fraction of the protein found in inclusion bodies may actually be functional31, as was shown, for 
example, in studies with dihydrofolate reductase or a form of β-galactosidase31,43. This points 
towards some native-like structure being present in the aggregates. 
When looking at the possible uses for this kind of aggregate, some intriguing ideas have 
been proposed recently. Studies from Wu et al.44 have highlighted a wide range of enzymes 
including: green fluorescent protein, β-galactosidase, β-lactamase, alkaline phosphatase, D-
amino acid oxidase, polyphosphate kinase 3, and others that have been observed to be produced 
as active IBs. These enzymes could be used practically, in inclusion body form as natural 
immobilized enzymes. In this case, the enzymes were produced when the enzyme was fused to 
another protein. With activities that in some cases rival the native protein43,45, these inclusion 
bodies are now of very high interest to not only those studying protein folding, or aggregation 
related disease, but also those looking to utilize their unique properties and put them to a 
purpose. 
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1.2.2.2 Relevance to disease 
As mentioned previously, proper protein folding is imperative to an organism’s health. 
Chaperone proteins are among the most abundant proteins in cells1 which supports the 
importance of proper folding, and aggregation is clearly linked to numerous diseases. In most of 
the diseases associated with aggregation, the mechanisms of disease pathogenesis remain 
unclear. Open questions include the roles of aggregates in a gain of toxic function, in which the 
mechanism of aggregation may be a synergistic combination of a mutation increasing a proteins 
propensity to aggregate as well as causing destabilization of the protein17 or if there are multiple 
factors, such as other proteins that contribute to the disease. Understanding more about these 
aggregates may lead to a clearer view on neurodegenerative disease pathology. 
1.3 Amyotrophic lateral sclerosis 
 Amyotrophic Lateral Sclerosis (ALS) is a relatively common and incurable 
neurodegenerative disease found around the world, which is characterized by the formation of 
protein aggregates in diseased cells. ALS has a lifetime risk of approximately 1 in 2000 46, with 
onset generally seen above the age of 47.47 It is characterized by various initial symptoms which 
may include muscle weakness and spasticity in the case of upper or lower motor neuron onset 
(cervical and lumbar onset respectively), or spastic dysarthria, where the speech is slow or 
distorted and a loss of the ability to swallow  in the case of bulbar onset.48,49 These three forms of 
onset are caused by a loss of motor neurons, however, the exact causes of the neuronal death are 
not well defined. 
There are two major classifications of the disease, those being the sporadic form (sALS), 
accounting for approximately 90-95% of cases, and the familial form (fALS) accounting for the 
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remaining cases6,17. The major causes of the more common sporadic form are still not 
understood, however a number of heritable factors have been identified as causal for fALS, all of 
which are associated with some cases of sALS as well, through de novo mutations. The first gene 
associated with fALS is the SOD1 gene, encoding for the aforementioned protein, which has 
been studied extensively, and accounts for approximately 20% of fALS cases. Additional genes 
have been subsequently identified including the most common mutated gene associated with 
ALS so far, the chromosome 9 open reading frame 72 (C9orf72) which accounts for 
approximately 40% of fALS cases, in which a hexanucleotide repeat expansion somehow leads 
to the disease. Mutations in other genes include TARDBP, encoding the TAR DNA-binding 
protein (TDP-43), and FUS, encoding the Fused in Sarcoma protein. 6,49,50. 
 Just as amyloid formation is the leading cause of some other neurodegenerative diseases, 
such as Parkinson’s and Huntington’s, aggregation is associated with ALS15–20. It has been 
previously proposed that the stability of SOD1 mutants may be compromised leading to 
aggregation, specifically aggregating in the form of insoluble oligomers termed “Lewy Body 
Like” hyaline inclusions as well as astrocytic hyaline inclusions26,27, round aggregates which 
build up in motor neurons. Fibril type (Skein-like) aggregates have also been reported in some 
cases51, and it has also been proposed based on mice and Chinese Hamster Ovary cell studies, 
that there may also be early forming soluble aggregates41,51,52. Detergent-insoluble SOD1 
aggregates are found in the late stages of the disease, located throughout the corticospinal tract, 
however not in the axons53.  Questions of the aggregate formation still exist, the ubiquitination of 
inclusions has been observed, which may implicate that the cell is forming inclusions as a 
defence mechanism, however, ubiquitination is not seen in all cases. 51 The mechanism of 
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aggregation is still unknown. Answering some of the questions about SOD1 aggregation may be 
useful for the development of a treatment. 
1.3.1 Therapeutic approaches 
With only one current drug on the market for the treatment of ALS, Riluzole, showing 
only slight benefits to the survival of patients 54, there is still a desire to better understand the 
disease with the goal of developing a more effective treatment. Riluzole itself is believed to have 
an effect on glutamate metabolism, but this is still not completely clear.54  Current approaches 
taken by researchers for the treatment of the disease include aiming at stabilizing mitochondrial 
stress55 as well as addressing the disease on the genetic level with stem cell therapy.  At least 42 
drugs have had negative human studies.54 Targeting the aggregation has not seemed particularly 
successful as of yet, however, academics, specifically Ray et al.56 as well as multiple 
pharmaceutical companies have taken an interest in that approach. These include Cambria, who 
had a small molecule compound in development for inhibiting SOD1 aggregation, Reata 
pharmaceuticals, who have identified a molecule capable of binding to, and stabilizing misfolded 
SOD1, as well as others.57. Studying the aggregation of SOD1 may serve dual purposes, by 
uncovering more information about inclusion body in general as well as acknowledging possible 
factors involved in a cause of ALS. 
1.4 Superoxide dismutase 
1.4.1 Structure 
As noted above, proteins play an important role in the life of organisms, they serve a 
number of purposes from serving a structural function to catalyzing important chemical 
reactions. One of these important proteins, that has been mentioned above, is superoxide  
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dismutase. There are several distinct forms of superoxide dismutase found both in eukaryotes 
and prokaryotes, including three distinct enzymes in humans: a cytosolic Cu, Zn – superoxide 
dismutase, referred to as SOD1, a manganese binding superoxide dismutase (SOD2) found 
primarily in the mitochondria58,59, and a second Cu, Zn – superoxide dismutase found in the 
extracellular space.60 The focus in this case has been the cytosolic human Cu, Zn-superoxide 
dismutase SOD1. 
Unlike the homotetrameric SOD2 or SOD3, SOD1 is a 153 amino acid homodimer, with 
a total molecular mass of approximately 32 kDa (Figure 1.4). Each monomer is composed of a 
Greek key β-barrel containing 8 β-strands, an electrostatic loop containing a short helical section, 
and a zinc binding loop, containing  histidine residues H63, H71, and H80 as well as aspartic 
acid D83 which bind to a single zinc ion. The single copper ion is coordinated by four histidines, 
including H46, H48, H120 and sharing H63 with the zinc ion. The zinc ion plays a structural role 
in the protein, with the copper ion participating in catalysis. Each monomer also contains 4 
cysteine residues, two (C57 and C146) form a disulfide bridge, and two are free cysteines (C6 
and C111).6 
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Figure 1.4: Ribbon diagram of the human Cu, Zn-Superoxide dismutase dimer. Each subunit is 
identical with the Copper (orange) and Zinc (black) ions visible on the right. The two longest 
loops are the Zn binding loop in yellow and the electrostatic loop in blue. The intrasubunit 
disulfide bond is seen near the bottom (red stick). Figure adapted from Broom et al.61 Original 
PDB 1HL562 
 
1.4.2 SOD1 function 
SOD1 is an enzyme that carries out the function of reducing the presence of the harmful 
radical superoxide. Since superoxide radicals are capable of causing damage within a cell in a 
number of ways, the removal of superoxide is an important function.63 The core of the active site 
of SOD1 includes the copper atom, and the surrounding amino acids to which it is bound, with 
other structures involved such as the electrostatic loop. When the copper is oxidized those amino 
acids are the histidines 46, 48, 63, and 120, with His 63 bridging between the copper and zinc 
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and being released by the copper upon its reduction.6 The copper is cyclically reduced and then 
reoxidized during the catalysis. The reaction catalyzed is a disproportionation reaction, with one 
superoxide ion being oxidized to form an oxygen molecule, and another then being reduced to 
form hydrogen peroxide. The overall reaction (Equation 1) is as follows6: 
 
Eq. 1                                      2 O2
- + 2H+ → H2O2 + O2 
 
The activity of SOD1 has been studied by various groups, including the Meiering Lab. 
One main general consensus is that some fALS associated mutations do in fact have an effect on 
activity, primarily those mutations with metal binding deficiencies. The majority, however, may 
still retain activity comparable to that of the wild type SOD1 given proper metalation40,64. 
1.4.3 SOD1 in ALS 
Due to recent studies showing that the loss of SOD1 function is not likely the cause of the 
disease, one well supported explanation is that the mutations in SOD1 may cause a gain in toxic 
function6,40,49,52,65, which may be associated with a structural change in the protein, or the 
aggregates. This is supported by the appearance of the inclusions at a later stage of the disease, 
not immediately. It has also been observed that soluble oligomers may gain a toxic function, 
possibly related to oxidative stress inside the cell.66,67 Some of the research in this area has 
focused on the identification of the products or interacting factors such as mechanisms requiring 
nitric oxide, or what form of SOD1 is involved, such as those deficient in Zinc, as Zinc is 
important for the enzymes stability 68,69. Also, SOD1 has been associated with peroxidase 
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activity rather than just dismutation, an increase in this activity has been observed with some 
ALS associated mutations, however, this may be protective70. Another change has also been 
proposed though, involving the auto-oxidation of the enzyme, resulting in the production of O2
- 
rather than the consumption of the toxic species.70 The gain of toxic function idea as a whole, has 
not yet been adequately explored, leaving key unanswered questions. 
Multiple types of mutations in SOD1, including deletions, C-terminal truncations, and, 
predominantly, point mutations have been implicated in causing the familial form of the disease. 
Approximately 182 mutations have been identified in patients diagnosed with the disease71. 
These mutations are widespread throughout the protein occurring in a range of locations 
including the metal binding region of the protein, close to the dimer interface, throughout the β-
barrel, and turns/loops (Figure 1.4). Some also show variety in the type of mutation for a single 
residue, for example mutation to a residue with a different charge, size, or level of 
hydrophobicity. The mutations have various phenotypes, in particular, variable disease duration 
(Table 1.1), ranging from more aggressive progression as seen with A4V or G41S mutations, 
with average disease durations of 1.2 and 1.0 years respectively to longer progression times 
associated with E21G, G37R, or H46R, with average disease durations of 17.2, 17.0, and 17.6 
years respectively17. The range includes mutants with average disease durations intermediate 
between these extremes. These are however averages and there is considerable variation among 
patients with a given mutation. For instance, individuals with H46R mutations have been 
observed to have disease progressions as short as 5 years and as long as 47 years.17  
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Table 1.1: The SOD1 mutants studied in this project, along with relevant statistics and 
information including: the average disease duration, the number of ALS patients that have been 
identified with the mutation, and the position of the mutation in the proteins structure. 
Mutant 
Average Disease 
Duration (years)17  
Number of 
Patients 17 
Mutation 
Position6 
A4V 1.2 205 
β-1 (Dimer 
Interface) 
G16S N/A N/A β-2 
G17S N/A N/A 
β-2 (Dimer 
Interface) 
G37R 17 27 Loop III 
G41D 14.1 15 Loop III 
G41S 1 16 Loop III 
H43R 1.8 12 β-4 
L84V 3.2 10 β-5 
G85R 6 11 β-5 
D90A 8 15 Loop V 
G93A 3.1 16 Loop V 
G93D 8.8 7 Loop V 
E100G 4.7 50 β-6 
L106V 1.9 6 Loop VI 
I113T 4.3 38 
Loop VI 
(Dimer 
Interface) 
L144F 11.8 15 Loop VII 
V148G 2.1 11 
β-8 (Dimer 
Interface) 
V148I 1.7 5 
β-8 (Dimer 
Interface) 
 
1.4.4 Wild type and pseudo wild type SOD1 
 Wild type SOD1 is the form of the protein found naturally in vivo, with no mutations. 
This form is useful for observing many characteristics such as the aggregation of the protein, 
however it is unsuitable for some thermodynamic studies. This is due to the necessity for a 
reversible folding process to obtain stability data through differential scanning calorimetry. The 
folding of SOD1 is not fully reversible due to the presence of two free cysteines at positions 6 
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and 111, which may form aberrant disulphide bonds upon denaturing and therefore not allow the 
protein to refold properly. In order to overcome this obstacle, in many previous experiments 
conducted by others72, as well as some experiments described here, the protein is expressed 
without the two cysteines responsible, changing them to an alanine and serine respectively. This 
allows the protein to reversibly unfold, allowing for the collection of thermodynamic data. This 
construct has previously been shown to retain similar catalytic activity and thermodynamic 
stability compared to the WT as well as other mutant variations and is therefore referred to as the 
pseudo-wild type (pWT) SOD1, a model comparable to the wild type40,73. 
1.4.5 SOD1 aggregation  
 The aggregation of SOD1 with relation to ALS has been studied extensively both in vitro 
and in vivo. The work that has been published ranges from experiments conducted in E.coli, to 
human embryonic kidney cells, to live mice19,39,74. SOD1 aggregation is the major focus of this 
thesis and as a part of the complex system that is a cell, a few of the many ways to continue 
studying this protein are explored here. Previous studies have shown that there are many possible 
pathways by which SOD1 may aggregate, including from the native state, misfolded states, and 
oligomers, however, the mechanisms are unclear. It is possible that mutant SOD1 may aggregate 
alongside WT SOD1 which may be misfolded due to oxidative modifications. Some of these 
misfolded forms may bypass the proteasome or autophagy49 and how SOD1 aggregates are 
involved in disease remains unclear. 
 Some who have focused on the aggregation of the protein in vitro include, from the 
Meiering lab, Stathopulos et al., Vassall et al. and Broom et al. 40,72,75,76 who have reported the 
formation of mutant SOD1 fibril type aggregates when the protein is destabilized. Although in 
 20 
 
some cases IBs have been shown to exhibit structural characteristics of fibrils33,34, and in vitro 
studies have provided information about SOD1 and many mutants, regarding the determination 
of aggregation propensities and aggregate metalation, in vivo studies also prove constructive. 
 In vivo studies have also been performed in multiple organisms, notably mice. Mice have 
been shown to exhibit the symptoms of ALS when fALS-associated mutants of SOD1 are 
overexpressed28,77–79. This makes them a good model for characterizing certain aspects of the 
disease and SOD1 aggregation. Mice models have various shortcomings though, including a long 
time period of development of disease (months in many cases), less mutations currently 
available, and relatively high cost. Therefore, cell culture models may prove to be more tractable 
in a number of ways, due to fast growth periods with large amounts of expression and, in the 
case of E.coli, a thoroughly studied host80. 
 In terms of inclusion bodies specifically, Leinweber and coworkers, have observed the 
formation of  IBs of A4V SOD1 in E.coli39. Also having provided some insight into IB’s of 
SOD1 in mammalian cell cultures were Prudencio et al.74, who have expressed multiple mutants 
of SOD1 in human embryonic kidney cells for the determination of aggregation propensities, 
however, with various important differences to this research, which will also be discussed further 
below. Finally, inclusion bodies produced in E.coli have been characterized in various ways by 
Furukawa, with a focus on the redox environment, a factor which is also very important when 
considering the experiments undertaken in this project81,82. All of the studies presented have been 
influential to the experiments conducted, and much of that work will be discussed in comparison 
to the results described in this thesis. 
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1.4.6 SOD1 metallation 
 The roles of both copper and zinc ions have been investigated in many studies of SOD1, 
including ones focusing on activity, stability and aggregation. Both metals affect the stability40, 
but the metalation of the protein is a complex issue due to the processes that SOD1 may undergo 
to become metallated. The metal centres of SOD1 are described above in section 1.4.1 and the 
metals and associated residues are illustrated in Figure 1.5. Structural details have been 
determined but the mechanism by which metals are acquired are not fully understood. The 
production of fully metallated SOD1 in E.coli has been shown to require special attention; the 
lack of the copper chaperone for SOD (CCS) leads to the mismetallation of the protein39. 
Coexpression of the chaperone or another method of copper loading may be applied to increase 
the level of copper present in the protein83. As the metalation of SOD1 is of great interest for 
both SOD1 aggregation and function/dysfunction, the presence of metals and any characteristic 
pattern of metalation for mutants may have multiple important implications. 
 
Figure 1.5: Metal centres of SOD1. The copper ion is orange and the zinc ion is blue. Bound to 
the copper ion are histidine residues H46, H48, H63 and H120. Bound to the Zinc ion are 
Histidines H63, H71, and H80 as well as aspartic acid D83. Note that Histidine H63 is shared 
between the two metal ions. Blue lines are nitrogen, red are oxygen, and grey is carbon. 
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 The major chaperone associated with SOD1 in eukaryotic cells is CCS, although there 
may be others. This chaperone protein, found in the cytosol, assists in the delivery of copper to 
the protein.83 The chaperone has three domains, the first is a copper binding domain structurally 
similar to another copper transporter ATX-1, which delivers copper to the secretory pathway. 
This first domain is one region of CCS responsible for metallating SOD, however is not 
absolutely required for SOD1 to gain copper. The second domain has a very similar structure to 
SOD1, but lacks a metal binding region. This second region is involved in recognition of the 
SOD1 target for metallation. The third and C-terminal domain is quite short, however, it has a 
copper binding region and unlike the first domain, is required for the chaperone to transfer 
metals to SOD1.84 Although the human SOD1 has been shown to take up copper through an 
alternative glutathione pathway in yeast cells85, it exhibits only 25-50% of the activity seen when 
CCS is present 85. There has not been any chaperone identified for zinc and its mode of delivery 
to the protein is not known. It has been shown in previous studies that the amount of Zn in the 
protein varies depending on the expression system.79,86 
 The role of metals in IB formation by SOD1 has received little attention to date, and is of 
interest for numerous reasons. Given that SOD1 in many studies is purified in the soluble form 
before experimentation discerning the metalation characteristics of the mutants, an open pathway 
of experimentation is the observation of metalation in mutant SOD1 aggregates formed in vivo, 
in this particular case, without the copper chaperone, which may lead to various partially 
metallated states39. This may also provide insight into the general characteristics of inclusion 
bodies. As mentioned in section 1.2.2., residual activity of inclusion bodies may be of interest for 
a large variety of reasons. Since such a large portion of proteins are metalloproteins, expanding 
our knowledge of inclusion body metalation could be key to their effective use in functional 
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applications. Two methods of metal analysis will be used here, specifically a recently developed 
procedure using the chelator 4-pyridylazo resorcinol (Figure 1.6), and inductively coupled 
plasma atomic emission spectroscopy, both of which have been used to measure the metalation 
of SOD1 previously87–89. 
 
Figure 1.6: Molecular structure of 4-pyridylazo-resorcinol (PAR). A metallochromic indicator, 
the molecule consists of a heterocyclic nitrogen group, an azo group, and an orthogonal hydroxyl 
group90.  
 
 PAR is a metallochromic indicator for a number of metal ions. When free of metal ions in 
solution, PAR has a maximum absorbance at approximately 416 nm.91 When bound to metals, 
the absorbance shifts to a longer wavelength creating a shoulder peak. The maximum of the 
shoulder depends on the metal bound. Spectrophotometrically, the concentration of a metal in 
solution can be determined by the PAR-metal complex absorbance.89,91 
1.5 Research objectives 
 Following extensive SOD1, research described in this thesis aims to expand our 
knowledge of mutant SOD1 aggregation in cells, using IB formation in E.coli as a model system. 
New information can be discovered which will complement the work of others, and lay a 
foundation for continued research. Here, the aggregation propensity of a set of chemically 
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diverse mutations distributed throughout the structure of SOD1 (Figure 1.7) are characterized. 
New characteristics will be revealed and may be compared to other information known about the 
mutations such as thermal stability, kinetic folding rate, and disease duration. It may also 
improve aggregation propensity prediction algorithms. By observing the metal status of the 
aggregates produced, a more detailed picture of the effects of mutations on SOD1 folding and 
metal binding can be developed.  
 
Figure 1.7: Ribbon diagram depicting the SOD1 dimer with sites of mutations expressed in this 
project highlighted as space filling residues. Each mutation location can be seen on each subunit 
of the protein. Figure adapted from Strange et al.92 PDB No. 2C9V 
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2.0 Methods 
2.1 Pseudo wild type (pWT) SOD1 expression and purification 
 ALS-associated mutations in a pseudo wild type (pWT) background were prepared using 
the pHSOD1ASlacIq vector (A pBR322 derivative) in an E.coli cell line, known as SOD-/- cells, 
devoid of the bacterial manganese and iron superoxide dismustases93. Cells were transformed as 
described by Miller94 with electroporation using an Eppendorf Eporator electroporation 
apparatus. SOD-/- cells stored in glycerol at -80°C were thawed and placed on ice. In a 0.1 cm 
electroporation cuvette, pre-chilled on ice, 40 µL of cells were mixed with 1 µL of a diluted 
DNA stock (5µg/mL). The cells were then electroporated at 1.80V. The cells were immediately 
suspended in 1 mL of sterile growth media containing tryptone, yeast extract, NaCl and glucose, 
then transferred to a tube and incubated at 37°C in an Isotemp Incubator (Fisher Scientific) for an 
hour. The cells were then concentrated by centrifugation ~0.9 mL of the supernatant was 
removed, the cells were resuspended and plated on LB-agar plates supplemented with 
chloramphenicol (30 µg/mL), ampicillin (100 µg/mL), and kanamycin (30 µg/mL), then once 
again placed in the incubator to grow overnight at 37°C. 
 A single colony was taken from the plate and used to inoculate 5 mL of LB broth 
supplemented with antibiotics, chloramphenicol (30 µg/mL), ampicillin (100 µg/mL), and 
kanamycin (30 µg/mL). The tube was incubated overnight at 37°C and at 200 rpm in an Innova 
4330 refrigerated shaker (New Brunswick Scientific). The next morning, 1 mL of the overnight 
culture was transferred into a 4 L flask with 1 L of sterile 2TY media (16 g/L Tryptone, 10 g/L 
yeast extract, 10 g/L NaCl in water) with the same antibiotics, chloramphenicol (30 µg/mL), 
ampicillin (100 µg/mL), and kanamycin (30 µg/mL). These cultures were incubated in the shaker 
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until the optical density (O.D.) at 600 nm reached between 0.6 and 0.8. At this point, the cultures 
were induced with 0.25 mM isopropyl-β-D-thiogalctopyranoside (IPTG), and both CuSO4 and 
ZnSO4 were added to final concentrations of 0.5 mM and 0.01 mM respectively. The cultures 
were incubated with shaking for a further 8 hours. 
Once the cells had been expressing SOD1 for 8 hours, they were transferred to 500 mL 
centrifuge bottles and pelleted by centrifuging at 4000g for 15 minutes at 4°C in a Beckman 
Coulter Avanti J-E centrifuge; the supernatant was discarded. An osmotic shock procedure 
adapted from Liochev et al.95 was used to obtain the periplasmic fraction. The cells were 
resuspended in 150 mL of 20 mM Tris at pH 7.5, 120 mL of 40% Sucrose, and 18 mL 250 mM 
ethylenediaminetetraacetic acid (EDTA). For some experiments, the EDTA solution was 
replaced by a nitrilotriacetic acid (NTA) or Diethylene triamine pentaacetic acid (DTPA) 
solution, the reasons for which will be described further in Section 4.4.1. The cells were gently 
shaken for 20 minutes on ice before being centrifuged again at 4000g for 25 minutes. The cell 
pellet was resuspended in 120 mL of MilliQ water and shaken again on ice for 20 minutes. The 
cells were finally centrifuged at 4500g for 45 minutes and the supernatant removed, flash frozen 
in liquid nitrogen and stored at -80°C. 
. The supernatant recovered from the osmotic shock was thawed and diluted in 20 mM 
Tris pH 8 and MilliQ water. Copper sulphate solution (100 mM) was added to a final 
concentration of 1.4 mM and the solution was heated in a 70°C water bath for 20 minutes. The 
tubes were cooled slowly at room temperature and the precipitate was centrifuged at 10000 g for 
20 minutes. Ammonium sulphate was added to the supernatant 30% w/v. The supernatant was 
then loaded onto a Waters column packed with Poros 20 micron HP2 resin using a Bio-rad 
Biologic Duo Flow chromatography system. A gradient program is run from 25% ammonium 
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sulphate to 45%. While observing the UV scan of the eluate, the fractions with any significant 
absorbance signal were collected and analyzed for SOD1 content by SDS-PAGE. The fractions 
containing SOD1 were pooled and dialyzed using 12-14 kDa Spectra/Por against 4 exchanges of 
MilliQ water. The protein solution was concentrated by ultrafiltration using a 10 kDa YM10 
(Amicon) membrane. Once concentrated to 3-10 mg/mL the solution was filtered using a 0.2 µm 
filter, flash frozen in liquid nitrogen and stored at -80°C. The concentration was determined by 
measuring the absorbance at 280 nm using a monomeric molar extinction coefficient of 5400 M-1 
cm-1,96 and the purity assessed by SDS-PAGE (15%), using the procedure in Section 2.3. 
2.2 pWT activity and melting temperature assays 
 Multiple assays were conducted to assess the metallation purified samples of pWT 
mutants of SOD1. These included a pyrogallol assay (adapted from Marklund and Marklund)97 
to determine the activities of each mutant and differential scanning calorimetry (DSC) to 
determine the melting temperatures. The pyrogallol assay was conducted by initially generating a 
reference scan using bovine liver catalase in potassium phosphate buffer (50 mM, pH 7.5), with 
8 mM pyrogallol, and assay buffer (50 mM Tris, 1 mM DTPA, pH 8.2). The solutions were 
brought to 25°C before mixing, once mixed in a polystyrene cuvette, the absorbance at 420 nm 
was measured for 2 minutes. Once the reference scan is obtained, an inhibition scan is generated 
by mixing catalase with the assay buffer, then adding a volume of the purified SOD1 solution 
and measuring at 420 nm for 2 minutes. The concentration of SOD1 to add is determined by trial 
and error to achieve approximately 50% inhibition of the activity.  
 Samples were prepared for DSC by mixing the purified SOD1 solution with Hepes buffer 
(20mM) and water. A reference solution containing the flowthrough of the proteins 
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concentration is also prepared. Both the sample and the reference solution are degassed before 
use. The DSC experiments were conducted on a VP-DSC microcalorimeter. The scans began at 
25°C and ramped up at a rate of 1°C/minute to a maximum of 100°C. The resulting data was 
taken to be analyzed using Origin software (OriginLab Corp.). After the subtraction of the 
refolding transition from the unfolding transition, the peak of the endotherm and melting 
temperature Tm was determined. 
2.3 Mutant SOD1 in wild type background expression and sample preparation 
 ALS-associated mutations of SOD1 were generated in the wild-type background, and 
expressed using the pET 21 vector together with the pLysS vector in the BL21 DE(3) E.coli cell 
line98, kindly provided by W. Colón. The pET vector encoded for SOD1 as well as the 
production of β-lactamase to provide ampicillin resistance. The pLysS plasmid encodes for the 
production of T7 lysozyme, which lowers background expression of target genes under control 
of the T7 promotor. The pLysS plasmid also confers chloramphenicol resistance. The cells were 
prepared two different ways, one smaller scale procedure was used for the determination of the 
SOD1 aggregation propensities described in Section 2.3, the other preparation, on a larger scale, 
was used to produce SOD1 for experiments for analyzing the metalation state of SOD1 inclusion 
bodies, described in Section 2.4. 
For the small scale production, the cells were grown from cell stocks by using the frozen 
cell stock to directly inoculate 10 mL of LB media supplemented with 100 µg/mL Ampicillin 
and 30 µg/mL chloramphenicol. The culture was then grown at 37 °C shaking at 200 rpm 
overnight, then a portion of this overnight culture was used to inoculate 50 mL of LB media 
containing the same final concentrations of antibiotics as the starter cultures. These flasks were 
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incubated with shaking at 25°C. When the cultures reached an optical density at 600 nm (OD600) 
between 0.7 to 0.8, IPTG was added to a final concentration of 0.1 mM. The flasks were then 
incubated at the same temperature and shaking speed for 4 hours. Samples of 1 mL were taken 
before the induction, at 2 hours of induction and at 4 hours of induction. These samples were run 
on an SDS PAGE gel to observe the expression over time. After the results of the first expression 
experiment were obtained, the sampling times were adjusted to be at 4 h, 6h, and 24h of 
induction time. 
 The 1 mL samples were centrifuged using an Eppendorf microcentrifuge at 12000 rpm 
for 2 minutes and 970 µL of supernatant was discarded. The cell pellet was then resuspended in 
the 30 µL of remaining media and 10 µL was removed for analysis as the whole cell fraction. 
The remaining 20 µL was then centrifuged again at 12000 rpm for 2 minutes. The supernatant 
was discarded and at this point the cell pellets were usually frozen at -80° C. When preparing the 
pellet for lysis, the pellet was resuspended in 30 µL of 10 mM Tris, 100 mM NaCl, and 0.1 mM 
EDTA (TEN buffer) at pH 8. 
 The lysis of the small fractions involved a series of freeze-thaw cycles. For the first 
freeze-thaw, the Eppendorf tube containing the sample was placed in liquid nitrogen for one 
minute, followed by placing it in a 37°C water bath for 5 minutes. Lysozyme and DNase1 were 
then added to the sample and the tube incubated in a refrigerator at 4°C for one hour. Finally, the 
tube was subjected to two additional freeze-thaws by the same method as the first. The sample 
was centrifuged at 12000 rpm for 10 minutes, then the supernatant was removed and analyzed by 
SDS-PAGE as the soluble fraction. The insoluble portion was resuspended in another 30µL of 
TEN buffer. To prepare the samples for gel electrophoresis, 15 µL of each of the soluble and 
insoluble fractions was mixed with 15 µL of gel loading buffer, and then mixed with 3 µL of 2-
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mercaptoethanol (BME). The samples were then boiled for 10 minutes and immediately 
centrifuged at 14000 rpm for 1 minute. The 10 µL whole cell fractions were prepared at the same 
time, using 10µL of loading buffer and 2 µL of βME, boiled and spun as above.  
The 12% SDS-PAGE gels were made and 10 or 15 µL of each sample was loaded in its 
respective well; initially the gels also included a lane with MW standards and they always 
included a 10 µg standard of previously purified pWT SOD1, necessary for densitometry 
calculations. The running of the gels is described in the next section. Variations of this cell 
growth protocol for sample preparation included cells grown in minimal media to observe metal 
free aggregation propensities, as well as expressing the proteins in LB at 37°C or 18°C to 
observe the effect of temperature on aggregation. 
 The metal analysis experiments required much more protein and so, the larger scale 
growths mentioned above were necessary. Following the same initial overnight growth period, 
the starter cultures were used to inoculate 1L of LB media in 4L Erlenmeyer flasks supplemented 
with chloramphenicol and ampicillin, which were then grown at 25°C to an optical density 
between 0.6-0.8 at 600 nm. IPTG was added to a final concentration of 0.1 mM and the growth 
was continued overnight. The cells were harvested the next day by centrifugation at 5000 g in a 
Beckman Coulter Avanti J-E centrifuge. For each litre of cells collected, the pellet was then 
resuspended in 15 mL 20 mM Tris/100 mM NaCl buffer pH 7.1. 
 The resuspended cells were then lysed using an Avestin Emulsiflex E5 emulsifier. The 
lysates were passaged three times using a minimum pressure of 17000 psi. The samples were 
centrifuged at 20000 g for 25 minutes at 4°C. The supernatants were discarded and the pellets 
were resuspended in a 0.5% (v/v) Triton X-100 solution, mixed and incubated for 30 minutes at 
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4°C. This sample was centrifuged at 20000 g for 25 minutes and the washing step was repeated, 
then the pellet was resuspended in 20 mM Tris, 100 mM NaCl, pH 7 buffer followed by 
centrifugation at 20000 g for 25 minutes to remove any residual Triton X-100. The pellets were 
flash frozen in liquid nitrogen and stored at -80°C until metal analysis, described in section 2.4 
below. 
2.4 Analysis of soluble protein expression in E.coli by gel densitometry 
Electrophoresis was performed using a Hoefer Mighty Small II and Fisher Scientific 
power source gel running system at 120 V. The 12% SDS-PAGE gels were run for a time of 
approximately 2 hours and thirty minutes. Once the electrophoresis was completed, the gel was 
stained using Coomassie Brilliant Blue (62.5% MilliQ water, 30% methanol, 7.5% Acetic acid, 1 
g/L Coomassie Brilliant Blue), then destained in 62.5% MilliQ water, 30% methanol, 7.5% 
Acetic acid, with rotation and a kimwipe to absorb excess dye. 
 Images of the gels were obtained using either a BIS303PC gel documentation system or 
an Alpha Innotech FluorChem FC2 imaging system, and analysed using the Total Lab TL100 
analysis software, using the 1D gel analysis function. Lanes were manually defined as were the 
SOD1 bands. Once this was complete, the standard pWT band was labelled with the known 
amount added (typically 10 µg) and the program normalized the values based on pixel density to 
obtain the mass of protein in the sample SOD1 bands. The background density of the gel itself 
was subtracted using a “rolling ball” method which involves the program determining peak 
limits by using a moving baseline. In the rare case that the software was unavailable for use due 
to the facilities computer maintenance, the program ImageJ99 was also used to determine the 
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relative pixel densities of bands on a gel, with the primary difference being that baseline of the 
band was determined manually.  
2.5 Determination of SOD1 aggregation propensity 
 Once the amount of protein from the soluble and insoluble fractions of a given sample 
was known, they were compared. The total amount of SOD1 was determined by adding the 
amounts for the soluble and insoluble fractions together. The proportion of the protein that was 
soluble was then determined by comparison to the total (Equation 2.1).  
(
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑆𝑂𝐷1 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
(𝑚𝑎𝑠𝑠 𝑜𝑓 𝑆𝑂𝐷1 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡+𝑚𝑎𝑠𝑠 𝑜𝑓 𝑆𝑂𝐷1 𝑖𝑛 𝑝𝑒𝑙𝑙𝑒𝑡)
) ∗ 100 = % 𝑜𝑓 𝑆𝑂𝐷1 𝑤ℎ𝑖𝑐ℎ 𝑖𝑠 𝑠𝑜𝑙𝑢𝑏𝑙𝑒          
Eq. 2.1                                                    
The percentage of SOD1 which was soluble was used as the measure of aggregation 
propensity. Therefore, those with a lower percentage soluble given the same conditions had a 
greater propensity to aggregate. 
2.6 Analysis of metal content of SOD1 inclusion bodies 
 The washed inclusion bodies were analyzed for metal content using two different 
methods: 1) a spectrophotometric assay using the chelator 4-pyridylazo-resorcinol (PAR), and 2) 
inductively coupled plasma atomic emission spectroscopy (ICP-AES). The former method was 
optimized for pWT and mutant SOD1s in the Meiering lab by a previous student100. The PAR 
assay utilizes a denaturant to initially unfold the protein and release bound metal to the chelator. 
The latter experiments required optimization including acid digestion to prepare the protein for 
the ICP instrument. 
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2.6.1 PAR assay for metal analysis of inclusion body samples 
 Necessary solutions for the assay were prepared beforehand, these included 8 M 
Guanidine Hydrochloride, a 400µM 4-pyridylazo-resorcinol working stock solution in 200 mM 
HEPES pH 8, 25 mM CuSO4 and ZnSO4 standard solutions and the sample solutions, consisting 
of Triton X-100 washed SOD1 mutant inclusion bodies. Inclusion bodies resuspended in 20 mM 
Tris/ 100mM NaCl buffer were added to the 8M guanidine hydrochloride solution and were left 
to unfold for at least an hour, as this was the average time at which brown inclusions were no 
longer observed and light scattering was not further reduced by extending the time. 
 When the unfolding was considered to be complete, PAR solution was mixed with the 
guanidine/protein solution or a guanidine/metal standard solution in a cuvette. The samples were 
scanned from 200 to 700 nm using a Cary 300 Bio UV/Visible spectrophotometer. The data were 
then analyzed using the program SpLab, developed by Dmitri Davydov (University of California 
San Diego) for spectral decomposition101. The two standard solutions spectra were used to 
calculate the portions of the protein spectra comprised of those metals and therefore the 
concentrations of those metals in their respective protein samples. 
2.6.2 Inductively coupled plasma atomic emission spectroscopy metal analysis of inclusion 
body samples 
 Sample preparation for the ICP-AES instrument calls for the sample to be fully soluble so 
it does not clog or stick to any tubing the instrument uses. The solubilising of the inclusion 
bodies was achieved by acid digestion. Samples of inclusion bodies resuspended in MilliQ water 
(5 mL) were placed in volumetric digestion vessels (Environmental Express) and concentrated 
Nitric acid (70%) was then added (at least 5 mL). Reflux caps were placed on the tubes and they 
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were then put in an aluminum block on top of a hot plate located in a fume hood and heated to 
approximately 100-105°C. The solution was refluxed for 3 hours, with more acid added if it was 
necessary to avoid the sample drying out. Once the samples were digested in the heating block, 
the tubes were removed and left to cool in the fume hood for approximately half an hour or until 
they were cool enough to hold. The volume was then made up to 20 mL using MilliQ water. The 
samples were filtered by plunging 2 µm FilterMate filters (Environmental Express) to the 
bottoms of the tubes. At this point, the tubes were capped. Controls were prepared in the same 
manner, along with a method blank lacking the inclusion body sample. 
 The High Dispersion Prodigy ICP-AES instrument (Teledyne Leeman Labs) was turned 
on and heated up to a temperature of 34°C the night before use to ensure a stable chamber 
temperature. The instrument is supplied a constant flow of nitrogen through an oxygen trap. The 
SALSA program was used to run the instrument and analyze data. Basic maintenance needs were 
dealt with as necessitated by the software, including making sure there was enough cooling 
liquid flowing in the instrument. Essential solutions prepared by the instrument technician 
(Ralph Dickhout, Chemical Engineering) were checked to make sure there are adequate volumes 
for the use of the instrument. These solutions included an internal standard solution of Yttrium 
(10 ppm), a rinse solution of MilliQ water, standard solutions of metals including Cu and Zn and 
also containing Na, Ca, Fe, K, Ni, Pb, Mn, and Mg in the same solution (although only Cu and 
Zn were measured), ranging in concentration from 3.2 mg/L to 160 mg/L for all metals, and a 
manganese peaking solution (10 mg/mL). 
 Once the instrument was ready to be used, Argon tanks were opened to supply the 
instrument and the flow rate was set to 1.0 L/min. The chiller was turned on and the standard 
solutions were placed in sample test tubes in a rack alongside tubes with rinse solution and the 
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manganese peaking solution. This rack was then loaded onto an autosampler. The inclusion body 
digests were then also loaded into test tubes in a rack and placed next to the standards. The 
samples were organized each time to avoid having the same samples next to each other, 
including the random placement of the controls and method blank to avoid any bias introduced 
by the preceding samples. 
 Once the samples were in place, the lines were locked against the pump. The method 
used was multiscan 20 IS in SALSA. The elements selected for measurements were Cu, Zn, and 
Y. The method was set to integrate 3 measurements of each sample. The plasma was started and 
the injector positioned to the manganese solution for peaking at 257.610 nm to detect the area of 
maximum ICP discharge and determine the optimum viewing angle of the ICP discharge. The 
instrument was then aligned to each of the standard metals using the 10 mg/mL solution, giving 
manual confirmation that each element’s maximum emission was present on the detector. The 
sample sequence was then run and the autosampler pumped each standard and sample to the 
plasma flame and the emission at 324.754 nm (Cu) and 202.548 nm (Zn) was recorded. 
 The concentrations of the metals of interest were determined by the program from a curve 
of the standards (Cu and Zn at concentrations of 3.2, 9.6, 16, 32, 80, and 160 mg/L. An example 
of the quadratic fit used for the standard curve is shown in section 3. Results were given in ppm 
along with deviations and relative standard deviations. These values of metal content in the 
solutions were then corrected for dilutions and compared to the protein concentration values of 
the original solutions obtained using densitometry data to determine the level of metallation of 
the SOD1 inclusion bodies. 
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3.0 Results 
3.1 SOD1 variants in pWT background  
3.1.1 Protein expression and purification 
 The pseudo wild-type mutants produced included A4T, L38V, L84V, and D90A. After 
growing and purifying the cells as described above, the purity was assessed by SDS PAGE of the 
final product and the yield by the UV absorbance at 280 nm. In each case, the only band 
observed for the gels of the final purified fractions was that for SOD1 (Figure 3.1).The yields 
were adequate for completing all further experiments with all three mutants. When A4T was 
purified using various chelators in place of EDTA, the results had little variation. The experiment 
when conducted with NTA provided slightly less yield than those with EDTA and DTPA. 
However, all three were capable of assisting the osmotic shock process and provided protein for 
analysis in another students experiments analysing the metal content of these mutants. 
 
Figure 3.1: SDS-PAGE gel lanes of purified pWT SOD1 mutants. No contaminant proteins are 
apparent in the final solutions of purified protein.  
 37 
 
 To measure the activity of the purified protein, a pyrogallol assay was conducted as 
described in Section 2.  The pyrogallol assays for the mutants all yielded similar results with 
activity (Figure 3.2) being close to that of the pWT SOD1 activity. The mutants had activities 
either higher or slightly lower than the typical pWT value of approximately 1800 units/mg40. The 
mutants D90A and L38V had activities of 2059.11 and 2053.33 units/mg respectively, while 
L84V was slightly lower at 1715 units/mg. 
 
 
Figure 3.2: Kinetics scans of the pyrogallol assay reaction. An amount of each mutant was used 
to achieve an approximately 50% inhibition of the reference scan, meaning each mutant showed 
significant levels of activity in inhibiting pyrogallol oxidation. From this data, the level of 
activity of a given amount of protein was determined. 
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3.1.2 pWT mutant melting temperatures 
Melting temperatures were measured using, differential scanning calorimetry for the 
mutants L38V and L84V. Adequate unfolding and refolding thermograms were obtained for both 
mutants (Figures 3.3 and 3.4). The most defined unfolding transition of the 20 Scans was taken 
and the following refolding transition subtracted. Apparent melting temperatures were taken 
from the peak of the endotherms for L38V and L84V. The apparent melting temperatures were 
determined to be 88° for L38V and 85° for L84V. The slight shoulder in the L38V thermogram 
may be due to some of the protein not properly metallated. 
 
Figure 3.3: Differential scanning calorimetry thermogram of SOD1 mutant L38V (0.5 mg/mL) in 
20 mM HEPES. The apparent melting temperature is 88°C. 
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Figure 3.4: Differential scanning calorimetry thermogram of SOD1 mutant L84V (0.5 mg/mL) in 
20 mM HEPES. The apparent melting temperature Tm was determined to be 85°C. 
 
3.2 SOD1 variants in WT background 
3.2.1 Expression of WT mutants  
 The expression levels of WT SOD1 and its mutants were all quite similar to each other, 
as determined by SDS-PAGE, throughout the experiments conducted. Representative results are 
shown in Figure 3.5. The expression time was optimized to yield a band of suitable intensity for 
quantitation by densitometry to be feasible with most mutants. The total amount of SOD1 
produced was approximately 9 to 12 µg per mL of cell culture at the 4 hours of induction time 
point (25°C); from 10 to 15 µg/mL at 6 hours of induction; and from 15 to 20 µg/mL at 24 hours 
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amounts of growth and expression, with final SOD1 yields between 1 to 9 µg after 4 hours of 
induction, depending on the mutant.  
 
 
Figure 3.5: SDS-PAGE gel with pellet and supernatant fractions of three examples of SOD1 
(WT, A4V, H43R), although the propensity of each to aggregate is different, the total expression 
of each was similar, based on the total SOD1 mass of supernatant and pellet fractions. The 
standard is purified pWT SOD1. Other significant sample components that can be seen here are 
lysozyme which is added during the lysis and what is likely the E. coli outer membrane protein 
OmpF39.  
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3.2.2 Preparation of WT variants for metal analysis 
 The washings of WT mutants described in section 2, yielded varying results in terms of 
amount of protein and quality. When produced on a large scale, a variety of coloration in the 
inclusion bodies pellet could be observed. When washed with Triton x-100, minimal changes 
were seen in the final product when run on a gel (Figure 3.6). Very few bands (proteins) were 
removed during the washing process. However, the size and coloration of the pellet had changed, 
the pellet was slightly smaller and usually became a paler brown colour. The proportion of 
protein lost was usually qualitatively similar for all bands, therefore SOD would be lost to a 
similar extent as any other remaining proteins. The change in the size of the pellet, however, 
implies the removal of other fractions of the cell not visible by SDS-PAGE.  
 
Figure 3.6: Gel of Triton X-100 washed pellets from E.coli cells expressing each mutant. Note 
the low level of SOD1 in the insoluble fractions of cells expressing WT SOD1 and H46R SOD1, 
two instances where SOD1 is largely found in the soluble fraction of the cell lysate. The standard 
sample of purified pWT SOD1 is 10 µg. 
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The inclusion body samples of WT SOD1 mutants described here contained 
predominantly SOD1 but also somewhat variable levels of contaminant proteins. Various steps 
were taken, however, to minimize contaminating proteins as well as separate the SOD1 from 
non-protein components of the cells. Several proteins with molecular weights of approximately 
23, 36, and 37 kDa proved recalcitrant to removal; these may be outer membrane proteins, such 
as OmpF, which was identified in the similar experiments by Leinweber and coworkers.39 
Although attempts were made to eliminate OmpF from the samples, this protein was consistently 
observed in the inclusion body fraction. Various speeds of centrifugation (Figure 3.7) as well as 
other detergents (Triton X-100, NP-40, Deoxycholate, SDS) did not separate the OmpF from the 
SOD1.  
 
Figure 3.7: SOD1 mutant V148G inclusion body samples in TEN buffer, centrifuged at different 
speeds for various amounts of time to assess if the E.coli OmpF could be separated from the 
SOD1. At lower speeds, as more SOD1 is left remaining in the supernatant after centrifugation, 
more of the contaminant proteins are as well. P indicates the pellet fraction, S is the supernatant. 
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 The fraction of insoluble material that was SOD1 in the large scale cultures, was variable 
depending on the mutant, and consistent with the results of the small scale aggregation 
propensity experiments below (section 3.2.3). The solubility of the SOD1 mutants when grown 
at 25°C in the small scale cultures, was consistent with the solubility when grown in the large 
scale cultures. The more soluble SOD1 mutants made up a smaller fraction of the total protein in 
the insoluble pellet compared to less soluble mutants, since there was a constant amount of other 
remaining proteins in the insoluble pellet. 
3.2.3 WT variant aggregation propensities 
 Initially, six mutants were chosen for the investigation of aggregation propensities. These 
mutants were characterized using various methods to optimize the experimental conditions for 
quantitation of IB formation. At 37°C, all mutants with the exception of I113T were 
predominantly (>95%) insoluble. This made 4 of the mutants (A4V, H43R, L84V, and G93D) 
essentially indistinguishable in terms of their propensity to aggregate (Figure 3.8). When the 
growth temperature was reduced to 25°C, a greater range of aggregation propensity for mutants 
was observed (Figure 3.9). The variability in O.D. at the induction time was also reduced at 25°C 
relative to 37°C, where the induction time was more difficult to predict and keep consistent as 
the cell growth passes through the logarithmic growth stage quickly in small culture volumes. 
When the cells were grown at 18°C, however, the cell growth was variable and unpredictable, 
with some cultures not growing to the necessary levels for induction. If induction was successful 
at 18°C, it was also very low, and not suitable for densitometry. 
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Figure 3.8: SDS-PAGE gels of whole cell (C), soluble (S), and pellet (P) fractions of E.coli cells 
expressing SOD1 mutants at 37°C for 4 hours. The majority of SOD1 is found in the pellet 
fraction with the exception of WT and I113T. The intensity of the band corresponding to SOD1 
was quantitated with reference to the standard of 10 µg of purified pWT. 
 
Figure 3.9: SDS-PAGE gels of whole cell (C), soluble (S), and pellet (P) fractions of E.coli cells 
expressing SOD1 mutants at 25°C for 4 hours. Mutants are more easily distinguishable by the 
fractions of soluble and insoluble SOD1 at 25°C compared to those grown at 37°C. The WT and 
I113T mutant are mostly soluble while G93D, L84V, and A4V have various amounts in either 
fraction and H43R is the most insoluble. The intensity of the band corresponding to SOD1 was 
quantitated with reference to the standard of 10 µg of purified pWT. 
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Initially, the final concentration of IPTG used was 1 mM in culture solutions, however it 
was of interest to see the effect that lowering IPTG concentration may have had on the solubility. 
IPTG concentration has been identified as a factor in the formation of inclusion bodies, since it is 
the molecule that initiates the over-expression of a non-native protein. By reducing the IPTG 
concentration in the growth procedure we can determine to what extent it affects SOD1 
solubility.102 The results (Figure 3.10) showed no clear change in solubility after a ten-fold 
decrease in IPTG concentration. 
 
Figure 3.10: Cell lysate fractions of samples grown at 25°C with two different final 
concentrations of IPTG during induction, 0.1 and 1 mM. 
 
In total, 19 mutants of SOD1 and the WT were analyzed for soluble expression at 25°C. 
The results of a minimum of 3 independent culture growths were averaged to determine the 
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aggregation propensity, with many more for some mutants. The averaged results for the 
aggregation propensities at 4, 6, and 24 hours of induction are illustrated in Figure 3.11 and 
listed in Table 3.1 along with other mutant properties which are compared to in section 4. Some 
independent cultures were also grown and analyzed by student Yi Yang, these values have been 
included in the data presented below. 
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Figure 3.11: Average % soluble of SOD1 mutants at 4, 6, and 24 hours of induction (top, middle, 
bottom respectively) at 25°C. The error bars are the standard error of the mean for the replicate 
experiments. A higher % soluble means a lower propensity to aggregate. Some variation is seen 
between time points. A wide range of aggregation propensities were observed. 
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Table 3.1: The WT background SOD1 mutants average % soluble after 4 hours of induction at 
25°C along with melting temperatures of the pWT background mutants in various metallation 
and disulphide statuses. Also included are folding rate constants. *includes some unpublished 
data. 
Mutant Region of Mutation Avg. % 
Soluble 
Holo 
Tm 
(°C)87* 
Apo-
Oxidized Tm 
(°C)88 
Apo-
Reduced 
Tm (°C)75 
Folding rate 
constant kf 103 
WT/pWT  N/A 80.11 92.7 59.1 47.6 0.04365 
A4V β-1 (Dimer Interface) 22.17 86.7 50.7 36.3 0.10715 
G16S β-2 30.61        
G37R Loop III 27.01   50.1 33.5  
G41D Loop III 41.04 86 45.2   0.04365 
G41S Loop III 29.50 84.4     0.01514 
H43R β-4 34.73 86.3 48.1 35.4 0.04365 
H46R β-4 20.36   55.6 52.6 0.04571 
L84V β-5 74.92       0.02399 
G85R β-5 31.26 77.5 54.7 40.7 0.02344 
D90A Loop V 42.30       0.02884 
G93A Loop V 72.13 87.7 47.9   0.04365 
G93D Loop V 33.74 85.1 45.6    
E100G β-6 38.14 86.2 51.2 33.2 0.03090 
L106V Loop VI 58.85       0.01995 
I113T Loop VI (Dimer 
Interface) 
29.20 88.2 47.1   0.02884 
L144F Loop VII 63.72       0.05248 
V148G β-8 (Dimer Interface) 71.62 86.9 49.3 34  
V148I β-8 (Dimer Interface) 73.26 92.7 60.5 51  
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 In Figure 3.11, a clear trend is evident, with mutants exhibiting a spectrum of solubility 
when overexpressed in E.coli. Only minor changes in % soluble are observed between repeated 
experiments. The % soluble generally decreases from 4 hours to later time points and is usually 
around a 5% change. In all cases, the WT SOD1 has the lowest propensity to aggregate, with the 
largest fraction remaining soluble. At the 4 and 6 hour time points of induction, the mutant with 
the largest insoluble fraction and therefore greatest aggregation propensity is H43R. This 
changes at 24 hours of induction though, as V148G, becomes increasingly more insoluble with 
increasing time of induction, dropping from an initial % soluble at 4 hours of induction of 38%, 
to 14% at 24 hours. The experimental uncertainties may be a factor in this distinction; it is 
generally larger at the later time points, and for a few mutants (V148G, G93D, L84V, G41S, 
G16S and E100G).   
3.4 Metal analysis of mutant SOD1 inclusion bodies 
3.4.1 4-Pyridyl-azo-resorcinol (PAR) measurements of metal in mutant SOD1 inclusion 
bodies 
 In order to investigate if inclusion body formation was influenced by metal binding by 
SOD1 and to explore whether the aggregates may have metals necessary for activity, the metal 
content determination using a spectrophotometric PAR assay was explored. The first series of 
experiments using the PAR assay produced results that gave highly variable data when analysed, 
with seemingly no methodical reason. The initial unfolding procedure yielded a clear colorless 
solution with no particulates seen in the cuvette. This was consistent for all of the SOD1 mutant 
washed inclusion body preparations. When the 4-pyridyl azo-resorcinol was added to these 
solutions, various amounts of colour were seen, ranging from no change in the metal-free yellow 
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PAR, to orange and red. At this point all solutions still appeared to be clear, with nothing solid 
observed in the cuvettes.  
 The absorbance spectra obtained (Figure 3.12) exhibited a slight increase in signal 
beginning at ~330 nm and increasing with decreasing wavelength. This may indicate some 
scatter from particulate matter in the sample, however, this was highly variable for each mutant. 
As a control, samples, once mixed and scanned were transferred to a small tube, centrifuged, and 
then scanned again. After the centrifugation, nothing was observed at the bottom of the 
centrifuge tubes, so there was no reason to assume any large amount of protein was lost from the 
sample, or that there were residual inclusion bodies. This also did not affect the slight incline 
associated with the spectra. Thus, no sedimentable aggregates were apparent in this experiment 
 
Figure 3.12: (Left) Spectra of PAR, metal standards complexed with PAR, and mutant SOD1 
resolubilized inclusion bodies with PAR. All samples contained 90 µM PAR, 45 mM HEPES 
buffer, with varying concentrations of protein. The large peak between 325 and 475 nm is due to 
uncomplexed PAR. When a sample containing metals is added, this peak is reduced and peaks 
ranging from 475 to 575 nm arise. (Right) A closer view of the metal bound PAR portion of the 
spectra, where copper has a maximum absorbance at approximately 535 nm, zinc at 
approximately 495 nm with a shoulder and the mutants with various levels of metals present.  
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 The spectra were analysed for metal content using SpLab software (figure 3.13), and 
among the mutants initially analyzed, A4V, had very little to no metal content, with WT 
seemingly having the most, and the other mutants H43R, H46R, L84V, and G85R having a range 
of metal concentrations in between. In the first trial, all mutants had larger amounts of copper 
than zinc, with anywhere from 1.25 times as much Copper compared to zinc (A4V), to about 25 
times more copper than zinc (H43R). The PAR assay works to varying levels of accuracy 
depending on what proportion of the sample is SOD1, and is accurate if SOD1 is the main source 
of metals in the sample. PAR also has spectral changes upon binding other divalent metals (e.g. 
Cd2+, Co2+, Ni2+)104, however, these are not expected to be present in significant amounts 
whereas copper and zinc have been added in excess to the growth media.  
 
Figure 3.13: SpLab results for metal analysis. The main window (right) with sample list and 
spectra data, spectra (bottom left), results window (top left) containing the amount of metal and 
PAR absorbance relative to the amounts of the standards, and fit parameters window (top center) 
where the order of polynomial is chosen and the standard spectra for reference. The panels 
shown are the analysis for a sample of E100G inclusion bodies. The protein spectrum in blue is 
analysed using the green 10 µ Zn standard spectrum and the red Cu standard spectrum to 
determine the amount of each metal present in the protein sample. 
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 Significant problems presented themselves upon the repetition of the experiment, with re-
growths of the same mutants. After having been prepared and analysed by the exact same 
method as the first trial, inconsistent results were obtained. The ratios of metal to protein subunit 
were vastly different between the two experiments. The values in the second experiment were for 
the most part much larger for Zn, and while some copper values were higher, for instance H43R 
had about twice as much copper, some values were also so low or fit so poorly that negative 
values were obtained. Interestingly, some values were now above a 1:1 ratio of metals to protein 
subunits. This implied, given accurate concentrations, that there was excess metal present in the 
sample, possibly from another metal binding protein, or that the metals are binding in non-native 
positions around or inside the inclusion bodies.  
 The experiment was repeated again for fresh growths of E. coli expressing the same 
mutants under the same conditions several times to eliminate the possibility that one set of 
results was due to a mistake made during one preparation. The results were that the metalation of 
the inclusion bodies was still highly inconsistent. The range of the values obtained for either 
metal, copper or zinc, in any of the mutants, was never consistent between any 2 trials in 5 
separate trials. It was soon after the completion of these experiments that small insoluble 
particles were observed, capable of binding PAR and forming a red pellet. Also observed after 
longer incubation was a clear gel-like substance in the sample Eppendorf tubes (Figure 3.14). 
These gel-like aggregates were resistant to disruption by a pipette, boiling, or the addition of 
SDS. However, the addition of a reducing agent, such as βME or tris (2-carboxyethyl) phosphine 
(TCEP) dissolved the aggregates. 
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Figure 3.14: Gel-like aggregate are removed from a 1.5 mL tube in which A4V inclusion bodies 
had been dissolved in GdnHCl as described in section 2.6.1. This particular gel was found after 
the sample had been sitting overnight and was approximately 2.5-3 mm long. The clear 
colourless gel was difficult to see in solution and was discovered when pipetting the solution. 
 
 Unfortunately, due to interactions between PAR and the reducing agents, the 
determination of accurate metal concentrations was unachievable. Both reducing agents above 
were tested with PAR to observe the effect on the spectrum. Some results can be seen below in 
Figures 3.15-3.17. Both of the reducing agents caused reductions in the metal-PAR complex 
absorbance for zinc and copper. In PAR assays conducted by Atanassova et al.105, TCEP had 
been shown to influence the relative intensity of Fe2+ and Fe3+ peaks, however, it was unknown if 
it would influence the peak height of copper and zinc PAR complexes or how it would do so.  
Since we did not find a reliable way to remove and measure the metals from the SOD1 gels using 
PAR, we explored measuring metal content using another method, ICP-AES. 
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Figure 3.15: UV/Visible spectra of A4V inclusion bodies in 90 µM PAR and 45 mM HEPES 
(blue), and the same sample after βME has been added to a final concentration of 0.1%. The 
absorbance for the metal-PAR complex from 500 nm to 550 nm is no longer observed upon 
addition of the reducing agent.  
 
Figure 3.16: UV/Visible spectra of PAR-Cu standard solution (25 µM CuSO4, 90µM PAR, and 
45 mM HEPES) and with the same solution when TCEP is added at different time points of 
incubation. 
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Figure 3.17: UV/Visible spectra of PAR-Zn standard solution (10µM ZnSO4, 90 µM PAR, and 
45 mM HEPES) and with the same solution when TCEP is added at different time points of 
incubation.  
 
3.4.2 Inductively coupled plasma atomic emission spectroscopy (ICP-AES) measurements 
of SOD1 inclusion body metal content 
 Acid digestion was chosen to dissolve the aggregates due to its previous use in protein 
sample preparation for ICP-AES106 and its ability to oxidize organic compounds, including 
proteins.107 The acid digestion conducted, from a visual observation, was capable of eradicating 
the gel-like aggregates. After approximately 4 hours of digesting, no solids were detected 
remaining in the solution, even upon centrifugation. To confirm this, a portion of the digestate 
was removed, neutralized using NaOH, and run on an SDS-PAGE gel. After staining, no bands 
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were observed from the digested sample, where as a control sample not digested but diluted to 
the same volume had clear bands observed. This gel indicated that the digestion was complete in 
breaking down all protein in the sample as was expected. After filtering the digested solution in 
the reflux tube, visual inspection of the filter also showed no signs of any buildup of solids. 
 As with the PAR experiments, multiple experiments were conducted in an attempt to 
obtain reproducible data. There were clear problems in the initial experiments, primarily 
associated with SOD1 variants with the lowest aggregation propensities. These included the WT 
SOD1 and the mutant G37R. The analysis values for both were extremely high for copper, and 
the WT was also extremely high in Zn. The amount of metals when compared to the amount of 
protein for WT SOD1 were 2674% metallated for copper and 147% metallated for zinc. Other 
mutants, including G16S, G41D, L84V, and L106V also indicated levels of metals that were 
higher than expected, however, not as extreme as those obtained for the WT and G37R samples. 
The copper levels for these four mutants were all between 117% and 206% metallated for copper 
with zinc levels between 80% and 127% Zn per subunit (Figure 3.18). These variants, unlike WT 
and G37R, do not immediately stand out based on their aggregation propensities. The remaining 
mutants (A4V, G41S, H43R, H46R, G93D, and V148G) yielded the lowest values between 1% 
and 63% metallation, for either Cu or Zn. 
 
 
 
 
 57 
 
 
Figure 3.18: ICP-AES metal analysis for acid digested inclusion body preparations of SOD1 
mutants. 100% metallated corresponds to a 1:1 ratio of metal: protein subunit, for Cu or Zn. The 
amount of metal varies markedly, between mutants and for repeated experiments (for example 
A4V#1,2 and 3). A4V expressed using M9 minimal media had no copper present and a very 
small amount of Zinc. Metal binding mutants, G85R and H46R are indicated with a *. 
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grown in LB with metals present, contains detectable metal. If the insoluble fraction contains 
metals but no SOD1, this would have to be either accounted for in the experiments where SOD1 
is expressed. The purpose of the latter control is to determine if there is any other source of metal 
in the experiment; the observation of inclusion bodies in a metal free culture would suggest that 
metals detected in the original experiments were from the LB media and added metal. Two 
additional mutants, G93A and G85R, were also grown for comparison, with one of the mutants, 
G85R, having known metal binding deficiencies. 
 The results of the repetitions for A4V were surprising in that, like the PAR data, they 
were still inconsistent. The initial results for A4V were that the metalation was 46% metallated 
for copper and 20% metallated for zinc. The repetitions, gave very different results, with the first 
repeat experiment yielding A4V inclusion bodies that were 121% metallated for copper and 95% 
metallated for zinc, and the second repeat experiment yielding A4V inclusion bodies that were 
255% metallated for copper and 150% metallated for zinc. All of these experiments were 
conducted under the same conditions, with the exact same methods used for growth, lysing, 
washing, protein concentration determination, and metal analysis. Given the identical conditions 
of the experiment, the results were surprising.  
The controls also provided interesting information. First, in the control of cells grown in 
LB media with no IPTG added to the growth, there was no SOD1 expressed in the cells, which 
was confirmed by SDS-PAGE. The procedure was continued, to lyse the cells, isolate the 
insoluble fraction (there was low levels of insoluble material), and analyze the metal content. 
The results showed that there was approximately 1 ppm copper and 0.2 ppm Zn in the control 
sample. Given that the metal content of SOD1-containing samples in many cases was over 10 
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ppm under the same conditions, this means that less than 10% of copper and less than 2% of the 
Zinc in the samples is attributable to remaining cell portions not associated with the SOD1  
Inclusion bodies. The metal free controls, using M9 minimal media, confirmed that the 
procedure used, including the tubes, buffer solutions, and acid digestion, added no further metals. 
The sample, once analyzed, had negligible amounts of both copper and Zn. 
The results of the two new mutants included were similar to those obtained previously for 
some of the other mutants. The G93A sample had significant levels of metal corresponding to 
109% copper and 56% Zinc. Given the results from the previous experiments, this was not out of 
the ordinary; for a mutant with no previous indication of metal binding problems, the copper and 
zinc levels were comparable to the other mutants. In contrast, the G85R mutant inclusion bodies, 
however, showed signs of lower levels of metals compared to most other mutants, as expected. 
The mutant showed 53% copper and 34% zinc. These numbers are comparable to those for 
H46R, another known “metal binding mutant” in which mutation of the Cu liganding residue 
H46 markedly decreases metal binding6. The only other mutant that showed similar and actually 
lower levels of metalation is A4V. The initial results showing A4V with very low levels of 
metalation, however, were not observed in the repeat experiments, and showed large variability. 
These results are summarized in Table 3.2. 
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Table 3.2: ICP-AES metal analysis for digested inclusion body preparations of SOD1 mutants. 
100% metallated corresponds to a 1:1 ratio of metal: protein subunit, for Cu or Zn. Also listed is 
the mass of SOD1 in the inclusion body sample analysed. 
Mutant Cu (%) Zn (%) 
Mass of SOD1 
analyzed (mg) 
A4V 46.08 20.51 87  
A4V 2 255.40 150.89 31.4 
A4V M9 -0.01391 1.708239 111.9 
G16S 206.37 99.14 16.3 
G41D 175.39 79.68 79.5 
G41S 57.39 43.95 78.2 
H43R 63.19 44.52 87.35 
H46R 38.39 23.76 4.05 
L84V 117.34 91.39 64 
G85R 53.57639 34.91376 145.7 
G93A 109.1329 56.08563 126 
G93D 8.52 3.81 64.05 
L106V 181.52 127.01 69 
V148G 1.71 0.92 68.2 
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4.0 Discussion 
4.1 SOD1 mutants in the pWT background 
4.1.1 Melting temperatures of L38V and L84V SOD1 variants 
 The SOD1 mutants L38V, L84V and D90A in the pWT background had no previous 
stability data from this lab, however, melting temperatures for L38V (apparent Tms of 56.5, 72.5, 
and 80.2 °C) and D90A (apparent Tms of 59.8, 75.5, and 82.9°C) in the wild-type background 
were found in multiple metalation states 96 and apo apparent melting temperatures for L38V 
(apparent Tm of 42.96°C) and L84V in the wild-type background (apparent Tm of 41.80°C) were 
reported by Rodriguez et al.108 The methods used by Rodriguez and coworkers differ from those 
used in the Meiering lab. Rodriguez and coworkers prepared mutants in the wild-type 
background using insect cells which produces proteins containing the natural N-terminal 
acetylation but generally incomplete metallation. This results in observation of multiple 
endotherms in thermograms owing to multiple forms of the protein that vary in metal content. 
This means a stage of deconvolution and analysis of what each peak represented had to be 
undertaken, with assumed relative stabilities that were in some cases supported by experiments 
on homogeneous samples of metalation states. In some cases, mutants had different numbers of 
endotherms, with some having three distinct peaks and others four.109 Other important factors are 
that the experiments conducted by Rodriquez and coworkers were conducted in phosphate 
buffer, which has been shown to decrease the apparent melting temperature by ~10°C, and since 
the wild-type background does not allow for reversible unfolding, the Tms are apparent, whereas 
the pWT background results in highly reversible unfolding.87 
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The values reported by Rodriguez et al. that are of interest in this case are the highest 
temperature endotherms, which would often correspond to the fully metallated holo form of the 
protein. For L38V the highest value was the “Tm3” or third endotherm, with a melting 
temperature of 80.2°C, for D90A, the highest endotherm recorded was 82.9°C. Although some 
mutants in the Rodriguez experiments obtained “Tm4”, ranging from 88.9 to 91.6°C for the “WT 
like” mutants, neither of these two mutants exhibited a fourth peak at this higher temperature96. 
In the experiments conducted here, the melting temperature obtained for L38V was 88°C, closer 
resembling a Tm4 of the previous studies. This possibly indicates that the melting temperature of 
a fully metallated species was not originally characterized but is here. As D90A has not yet been 
analysed by DSC here, this may give reason to do so, as it seems likely a fully metallated melting 
temperature of that mutant may also not have yet been characterized. 
4.1.2 pWT background SOD1 enzyme activity 
The results of the activity assays are an indication that the protein purified was well 
metallated. This means the major endotherms observed in the DSC experiments are most likely 
for the fully metallated species. This is also supported by how high the melting temperatures are 
compared to the pWT and other mutants previously characterized by members of the Meiering 
Lab87, as well as the Tm3 values reported by Rodriguez et. al.
96 The melting temperatures indicate 
a slight loss in thermostability of the mutants here compared to pWT (Tm of 92°C at 0.5 mg/mL, 
which increases with increasing protein concentration87) , however, they are still very stable 
compared to other mutants, in particular compared to more destabilizing mutations in metal 
binding regions. 86 
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4.2 Expression of fALS associated SOD1 variants in the WT background in E.coli 
4.2.1 Sample preparation of insoluble SOD1 
 Examples of the mutant expressions from the Colon lab, from where the cells used in 
these experiments were obtained, were very similar to the levels observed when the cells were 
grown and induced under the same conditions in this lab. In these experiments all 19 mutants had 
similar levels of expression at 4 hours of induction, and this was consistent for each temperature 
tested. The growth however, was variable when cells were grown in minimal media. The cultures 
did not all grow and if they did, they did not necessarily grow at the same rate from one 
experiment to the next. This limited the ability to compare the results for any metal free growths 
with those for metal supplemented rich media. 
Not all problems were associated with growth in minimal media, another issue described 
in Section 3 was the inability to remove contaminant proteins from the SOD1 IBs. Ideally, the 
contaminant protein OmpF would have been removed, however, as this proved difficult, its 
presence was tolerated because OmpF is a porin that transports small hydrophobic molecules110 
and has not been found to bind metals. The end result still produced samples where the most 
aggregation prone SOD1 mutants constituted greater than 80% of the insoluble proteins isolated 
from the cells. Although OmpF was initially a concern, it may have revealed more about the 
composition of bacterial inclusion bodies. Regardless of the centrifugation speed used for 
obtaining the insoluble portion, or the type of detergent (Triton X-100, NP-40, Deoxycholate, 
SDS) used for the wash steps, SOD1 and OmpF were consistently found together. This may 
indicate that OmpF is either integrated into the inclusion bodies, or stuck to them in some way. 
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Previous studies have reported that outer membrane protein expression is increased during cell 
stress111,112. This may in itself cause those outer membrane proteins to misfold and aggregate 
along with the overexpressed protein of interest. In another experiment conducted in the 
Meiering lab, centrifugation was able to separate the inclusion bodies of another protein domain 
expressed in E. coli from OmpF by adjusting the centrifugation speed, however, this was not 
effective for SOD1. Thus, it may be specific properties of SOD1 that allow the OmpF to stick to 
or be included in their inclusion bodies. 
4.2.2 Aggregation propensity analyses for SOD1 variants; predicted and measured 
propensities and relationships with ALS disease characteristics 
 When comparing the aggregation propensities for SOD1 variants in E.coli to various 
other characteristics of SOD1 and or ALS, a number of interesting correlations arise. Many 
characteristics of SOD1 mutants have been reported by many different research groups. Some 
that are of interest here are the melting temperatures of SOD mutants in various metallation 
states, in order to attempt to connect the thermal stability of a given mutant to its aggregation 
propensity. Others include the kinetic folding rate of the mutants, the average disease durations, 
and in the following sections, the metallation state of the SOD1 IB’s. 
 The information revealed by the aggregation propensity data itself is a prime example of 
the effects that different mutations may have on a protein. Although the range of propensities 
was measured at one specific temperature to maximize observed differences between mutants, 
this method highlights that mutations may cause marked differences in protein characteristics. 
Although mutations promoting aggregation has already been observed and compared with 
stability for other proteins, for example HypF-N113, observing the aggregation propensities of 
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SOD1 mutants in vivo had been limited to few studies. These include the study of A4V mutant 
inclusion bodies in E. coli 39 and the formation of IB’s by many different mutants in human 
embryonic kidney cells74. The study conducted by Prudencio et al.74 has multiple differences 
from the studies described here. For example, the kidney cell line may have important cellular 
machinery (such as the copper chaperone for SOD1) for folding SOD1 that E.coli lacks. Another 
difference is their choice of sonication as a cell lysis technique. Using sonication with SOD1 
which still has the free cysteines present has been shown to cause aggregation.76 This may make 
all mutants seem more aggregation prone than they actually are. 
 When the aggregation propensities measured here are compared to multiple thermal 
stability data sets (Summarized in Table 3.1 and shown in Figure 4.1), some trends with each 
data set are observed. In the correlations generated here, each set of thermodynamic data shows a 
clear relationship to the aggregation propensity. The available thermodynamic data differs 
somewhat for the different forms of the protein, with 13 mutants oxidized apo melting 
temperatures known, 12 for holo, and 9 for reduced apo melting temperatures having been 
determined as of now, however, all available data was used in order to observe any trends. When 
using all available data, the thermodynamic data set with the greatest correlation to aggregation 
propensity, is that of the reduced apo melting temperatures, with a squared correlation coefficient 
(r2) of 0.609 and a P value of 0.013, significant at P < 0.05. The oxidized apo melting 
temperatures when compared to the aggregation propensities also show a clear trend, (r2 = 
0.5094, P = 0.00615), with the holo comparison having the worst r2 at a value of just over 0.3 
and a P value of 0.062 (not significant at P < 0.05). 
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Figure 4.1: Comparisons (left) and correlations (right) of the aggregation propensities determined 
here to previously measured melting temperatures of SOD1 mutants with various metalation and 
disulfide statuses. (Top) The holo SOD1 mutant melting temperatures, (middle) the reduced apo 
melting temperatures, and (bottom) the oxidized apo melting temperatures compared to 
aggregation propensities. 
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An interesting outlier is found in the holo correlation plot, the mutant G85R. This mutant 
in particular, has been identified to alter metal binding. When that data point is removed from the 
plot (Figure 4.2), the r2 increases to 0.61. The remaining plots with the G85R mutant removed, 
also see an improvement, however, the reduced apo is still the most correlated.  
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Figure 4.2: Correlation of aggregation propensity to melting temperatures with the removal of 
metal binding mutant G85R. 
A final question regarding the ability to properly coordinate the DSC obtained data to the 
aggregation propensities, is whether they change substantially in the presence of the proper 
chaperone for copper metalation. If the copper chaperone assists the mutants to different degrees, 
some mutants may change position in the correlation. Determining if this is a factor may have 
implications for the study of aggregation with other metalloproteins. This could be an interesting 
direction for future research. 
With these correlations, a number of new questions arise. Some of these include, whether 
the aggregation propensities better match the thermodynamic data of a certain metalation state 
(e.g. Apo or holo), how much can we determine from comparing a characteristic obtained in vivo 
to one that was observed in vitro, and whether any correlations hold true for multiple proteins 
from other studies. Other proteins that have been studied for similar characteristics include the N 
terminal domain of the E. coli HypF (HypF-N)113 and some of its mutants, the spectrin SH3 
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domain (SPC-SH3) and some its mutants9, Interleukin-1β and some of its mutants, as well as the 
human p53 core domain (p53C) and its mutants.114 
In comparing to the other studies mentioned above, a consensus is not reached. Although 
Mayer et al. do not report the % soluble for their protein of interest, they conclude that the level 
of soluble protein is decreased with decreasing thermodynamic stability, as this was the case 
with the p53 core domain.114 Castillo et al. show results supporting that aggregation propensity is 
controlled by thermodynamic stability based on the data produced using the SPC-SH3 domain 
model.9 Finally, Chrunyk et al. state their observation of no strong correlations of the Interleukin 
-1β inclusion body formation to thermodynamic or thermal stability.115 This final study is in 
contrast to the others, as well as to the correlation observed here with SOD1. Therefore, although 
there are multiple studies supporting the correlation between aggregation propensity and thermal 
stability, this may not be true for all proteins. 
 The rate of folding for mutant SOD1s has been studied previously by members of the 
Meiering lab and others.103,116 Comparing the kinetic folding rates to the aggregation propensities 
(figure 4.3), there is a clear outlier, A4V. The folding rate constant for A4V at >0.1 s-1 is much 
larger than the next highest value; this has been observed independently by both the Meiering 
and Oliveberg groups. Whether A4V is included or not, no significant correlation is observed 
between the folding rate and the aggregation propensity of SOD1 mutants expressed here. 
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Figure 4.3: Comparison of the kinetic folding rates to the aggregation propensities of SOD1 
mutants. Top: with A4V. Bottom: with A4V removed.  
 It has been noted that different SOD1 mutations are associated with different disease 
durations17 and the relationship between disease duration and mutant SOD1 aggregation 
propensity has been investigated in the studies mentioned above by Wang et al.17 and Prudencio 
et al.74 Using the % soluble data obtained here, there may be a trend that disease duration 
increases with increasing variant solubility (Figure 4.4), however, the r2 of 0.1302 and P value of 
0.1548 are relatively low values and the trend is not significant. As seen in section 3 the data 
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obtained here shows a lack of correlation between the average disease duration and the 
aggregation propensity of the fALS associated SOD1 mutants. The results obtained here are 
roughly in line with the results of Wang et al.17 or Prudencio et al.74 The study from Wang et al. 
had compared the disease duration in a more complex model, including both protein stability and 
a calculated aggregation propensity obtained from a recalibrated version of the Chiti-Dobson 
equation. The authors concluded that this method revealed a correlation with disease duration, 
reporting an R value of 0.58 (R2 = 0.34). The study from Prudencio et al. showed that when 
grouped into relatively loose categories (low, moderate, high, and extreme measured aggregation 
propensities), mutants with a high aggregation propensity have a shorter disease duration, 
however, when all considered together, like the data presented here, no statistically significant 
correlation was observed. 
 
Figure 4.4: Comparison of the average disease duration and aggregation propensity of fALS 
associated SOD1 mutants. 
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affect the aggregation propensity is not clear. A comparison between the same mutants used in 
the two studies shows differences with many mutants relative to each other. For example, in the 
experiments conducted here, H43R and A4V had the highest propensities to aggregate, yet, in 
the Prudencio study, mutants such as L84V, G41S, V148G and E100G all had greater 
aggregation propensities than either A4V or H43R. On the other hand, similar results for 
aggregation propensities were observed for some mutants, including V148I and L144F, which in 
both cases were among the least likely to aggregate.74 Overall, it seems the two studies provided 
somewhat different results. There could be multiple reasons for this arising from differences 
between E. coli and human cells, and experimental protocols used to express and analyze the 
SOD1 variants. This raises questions about what can be done in further studies to provide the 
most useful information for understanding the results and their relation to ALS characteristics, 
such as expressing the CCS in E.coli.  
One shortfall of the average disease duration data is the lack of large patient sample sizes. 
Various researchers have reported their results on the disease duration of specific mutations they 
have investigated, and although some have attempted to combine data from others reports, the 
numbers may not be large enough yet to have a good idea of the actual average disease duration 
for those mutants. This is especially evident looking at the work of Wang et al.17 versus the work 
of Andersen et al. where both have looked at 15 patients with the D90A mutation (with the 
information of 2 patients from Andersens study also taken into account in the Wang report). 
Andersen reported an average disease duration of over 14 years117. However, Wang reported an 
average disease duration of 8 years17. Thus, limitations in patient data are a significant limiting 
factor in identifying clear correlations with SOD1 characteristics. 
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 There are a number of possible additional explanations for the absence of a clear 
correlation of patient disease duration with protein solubility measured here. A major possibility 
is that the fully formed insoluble aggregates of SOD1 are a byproduct, or only one further stage 
in the disease ALS.118 Keller et al. have reported evidence that many mutant proteins in various 
genes that are associated with ALS are involved in the larger system of RNA metabolism, as 
evidenced by the co-localization of ALS-mutant TDP-43 and FUS in cytoplasmic inclusions.119  
Other studies have focused on the involvement of soluble oligomers as the cause of disease.41,120–
122 Studies by Banci et al.41 Redler et al.121 and Grad et al.122 have attempted to identify and 
characterize the early stages of SOD1 oligomerization, with the hope of identifying a soluble 
oligomer with characteristics that may reveal more about the disease progression. Grad et al. 
have proposed that these misfolded mutants or soluble aggregates may efficiently propagate 
misfolding between cells.122 These ideas do not completely rule out that the insoluble inclusions 
are still a factor in the disease. The relationship of the level of large soluble aggregates formed in 
model cellular systems, such as E. coli and human cell culture, to the types of aggregation 
occurring in disease is complex and not yet well understood. 
As mentioned above, the aggregation propensity data used by Wang et al.17  was 
predicted using an algorithm, which is based on physical properties of the proteins amino acid 
sequence (such as hydrophobicity, charge and secondary structure propensity). In the past 
decade, many algorithms have been developed to attempt to predict whether a mutation may alter 
a protein’s propensity to aggregate. This may be by analysing the sequence surrounding a 
mutation or by the chemical differences presented by the change of an amino acid. Some of these 
include the previously mentioned Chiti-Dobson equation23 and the related Wang-Agar 
adaption17, as well as Zyggregator25, Ztox25, fold-amyloid123, Pasta124, Tango24, Waltz125, and 
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Profile 3D126. All of these algorithms have been used previously to analyze SOD1 mutants with 
values calculated and normalized by Heather Primmer.127 Comparison of the predictions (Table 
4.1) with the levels of aggregation measured here (Figure 4.5), shows that none of the predicted 
propensities correlates strongly with the experimental data.  
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Figure 4.5: Aggregation propensities of selected SOD1 mutants as determined by various 
prediction algorithms vs. the aggregation propensity as determined by inclusion body formation 
in E.coli. A table of the normalized aggregation prediction values is shown in Appendix 1. 
 With respect to expanding our knowledge of inclusion body formation in general, the 
data obtained are also quite interesting. Although stages of the optimization process, such as 
temperature control have already been thoroughly studied13,128,129, the wide range in different 
aggregation propensities given single point mutations, specifically in SOD1 has shown how 
small changes in a protein can yield a full spectrum of results. Ideally, identifying the underlying 
factors that lead a specific mutation to a specific result would lead to more control in protein 
design. For example, designing a protein to be very insoluble, yet active. When we look closely 
at the mutations in SOD1 studied here, there are many examples of various changes, such as 
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mutations in the metal binding regions (G85R, H46R), in the dimer interface (A4V, V148G/I), as 
well as throughout the rest of the protein. 
 Different mutations at the same location in SOD1 have shown here to have varying 
effects. For example, the multiple mutations at the 41st, 93rd, and 148th amino acid positions have 
shown some interesting variations. The two mutations at the 41st position, G41D and G41S have 
similar aggregation propensities, as do two mutations at the 93rd position, G93A and G93D. 
Unlike those mutations, V14G and V148I have very different propensities to aggregate, with 
V148G being much more insoluble after 4 hours of induction at 25°C. Although this is a small 
sample size, it further supports the hypothesis that different mutations, even at the same position 
can have variable effects, which would be of interest to investigate further. One study that has 
focused further on this question is from Pratt et al.130 specifically on mutations in the 93 position, 
labelled as a “hot spot” with 6 different mutations associated with fALS. Each of those mutations 
presented with a distinct clinical phenotype and the aggregation of each was observed with a 
small-angle x-ray scattering assay to determine the aggregation propensity in vitro. Looking at a 
single position in a complex protein simplifies comparisons of the effects of mutations between 
regions of SOD1 (metal binding, dimer interface, etc.). While the Pratt study concluded once 
again that there was a correlation between mutant aggregation and disease, the results here 
suggest that a different “hot spot” may give a different range of effects than ones at another 
position. This is simply analysing the effects of the mutations themselves, the resulting changes 
to the protein from mutations or the process of aggregation, such as the loss of, or partial binding 
of metals is also a major aspect of interest. 
 
 77 
 
4.3 Metal analysis of SOD1 inclusion bodies 
4.3.1 PAR spectrophotometric analysis of metal content of SOD1 inclusion bodies 
All of the results obtained by PAR became questionable upon the discovery of 
transparent gel-like substances in the guanidium hydrochloride / inclusion body samples. After 
allowing samples of A4V to sit at ambient temperature overnight, one of these clear colorless 
gels became apparent when the sample was pipetted. It was very flexible and would not break up 
easily with intense pipetting or vortexing. Multiple methods were used in an attempt to break up 
the gel-like aggregates, as described in Section 3.4.1, including: mixing vigorously with a 
pipette, vortexing, boiling, and boiling with added SDS. Those attempts only resulted in smaller 
pieces of the gel. It was not until the addition of reducing agents that the gel dissolved, revealing 
that the gel was most likely formed from aberrant disulphide crosslinking. 
 After searching the literature, it was apparent that similar gels have been observed in 
other studies with SOD1, however, none of these described the gels in detail or analyzed their 
structure. Lindberg et al.131 reported gels in their in vitro studies of SOD1 variants. They did not 
describe structural details of the gel, but the aggregates did not stain with the amyloid binding 
dyes thioflavin T or Congo red. Based on the experiments conducted here, these gels likely retain 
some bound metals. At the later time points of incubation with PAR, there were very small 
insoluble pieces that showed signs of metal binding. These were only apparent upon closer 
observation and became a red colour in contrast to the more yellow background of the PAR 
solution (Figure 4.6). There is a possibility that these were portions of the original inclusions that 
may not have been dissolved in the guanidine due to disulphide crosslinks. This seems unlikely 
though due to the great majority of the inclusion mass dissolving in the guanidine, and the 
inclusions being formed in the reducing environment of the E.coli cytoplasm132. It seems likely 
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that upon incubation of the IB sample in denaturant, after protein was solubilized, it may have 
oxidized to form a gel, perhaps by adding to small particles of undissolved material. 
 
Figure 4.6: Sample A4V inclusion bodies denatured in 5.4 M GdnHCl with 90 µM PAR, and 45 
µM HEPES. Samples was denatured overnight. After the addition of PAR, small pieces of 
insoluble material become apparent as the more deeply coloured orange/red compared to the 
yellow solution when bound to PAR. This colour change may be expected if PAR is binding to 
metals that have a higher concentration inside the particles than in solution. 
 
It has been reported in multiple studies that wild-type and mutant SOD1 can aggregate 
due to the formation of intermolecular disulphide bonds involving the free cysteines Cys 6 and 
Cys 111, although these bonds do not appear related to the disease.39,131–136 The experiments 
conducted are also consistent the ability of the protein to form intermolecular disulphides and 
gel-like aggregates either within inclusion bodies or from the unfolded state in guanidine, on the 
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approximate time scale of hours. This imposes limitations on the quantitative analysis of metals 
using PAR.  
As the experiments here are a new application of the PAR assay, it was important to 
identify any possible cause of error. The procedure initially used by Crow et al. 89 involved the 
use of PAR along with other chelators (NTA and EDTA) to analyze the metal content of SOD1. 
The purposes of the chelators were to specifically bind and sequester either Cu or Zn from 
binding PAR in order to enable specific analysis of both metals. This method was adapted by 
Colleen Doyle in the Meiering lab100 to eliminate the other chelators, and instead use the spectral 
decomposition software SpLab to fit the components of absorbance arising from free PAR and 
PAR complexed with Zn or Cu. The results for the new PAR method were compared to results of 
the same samples analyzed by ICP-MS. Notably, residual EDTA from the purification procedure 
interfered in the PAR assay such that it decreased the apparent levels of Zn compared to the ICP-
MS values. Attempts were made to overcome this obstacle in the experiments described here, 
specifically the purification of the pWT SOD1 mutants. This was the reason that some of the 
purifications used NTA or DTPA as described in section 2.1. Unfortunately neither of the 
alternative chelators was a suitable replacement, with both still sequestering some metal from 
PAR. EDTA is a common component in cell lysis buffers and other solutions used during protein 
sample preparations, and it is known to also bind very tightly to SOD1137; thus the presence of 
EDTA is very important to take into account when analyzing metal content of proteins, in 
particular SOD1, using PAR.  
Due to large variations in the apparent metal content of IB samples as measured by PAR, 
the insoluble gel-like aggregates, and the inability to use reducing agents due to their interference 
with the PAR spectra, another technique was deemed necessary to analyze the inclusion body 
 80 
 
metalation. What had been consistently been used by others previously to determine the metal 
content of SOD1, was ICP-AES.82,106 More on the details of this technique are discussed below, 
however, the PAR technique was also revisited. To validate results obtained from PAR, the PAR 
experiments were conducted using the sample preparation method also used for the ICP-AES 
procedure. Differing from the technique of using denaturant as in the Crow89 and Doyle100 
assays, this sample preparation method was the acid digestion described in Section 2.6.2. When 
the solution was neutralized to not affect the PAR spectra, the results loosely agreed with those 
obtained from using the ICP-AES. A comparison of the techniques is continued in sections 4.4.3 
and 4.4.4 
4.3.2 ICP-AES analysis of SOD1 IB metal content 
The results of the ICP-AES experiments clearly showed that the inclusion body samples 
of SOD1 contained at least some metals, in agreement with the PAR assay results. With a more 
reliable method of denaturing the inclusion bodies by simply acid digesting them, ICP-AES 
provided results unimpeded by the hydrogel type aggregates unveiled during the PAR 
experiments. Unfortunately, the experimental method showed increased relative uncertainties for 
SOD1 mutants with lower aggregation propensities. The numbers were severely skewed in the 
direction of large amounts of metal per subunit of SOD1 when the mutant expressed was mostly 
soluble and there was consequently smaller absolute and relative amounts of SOD1 in the 
inclusion body sample. This could be in large part due to excess metals binding other remaining 
portions of the cell. Normally, when SOD1 comprises the majority of the insoluble sample, the 
fractions of the cell remaining after washing have much less effect. This may change when the 
amount of SOD1 in inclusion bodies is very low, the majority of the pellet is then other protein 
and likely other cell material. Due to the same washing procedure being used for all samples in a 
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given experiment, this does not account for instances where 2 samples of the same mutant 
prepared by the same procedure showed different metalation. 
 One case where this was in fact a problem was with 2 separate samples of the mutant 
A4V. In two separate trials of determining the metalation of A4V inclusion bodies, one result 
had a relatively low level of metalation, with approximately 40% Cu, and 18% Zn, and a second 
sample prepared later yielded 120% Cu and 95% Zn. With the entirely same procedure, two very 
different results were obtained. This may be an indication that the procedure has a major flaw; on 
the other hand the PAR results also showed high variability. Thus, it is very likely that the level 
of metalation of inclusion bodies is truly variable.  
4.3.3 Comparison of Techniques 
Due to the large variability in the initial PAR experiments, and the new procedure being 
used, it is important to validate the technique. Both the PAR assay and ICP-AES have benefits 
and shortcomings for determining the metal content of SOD1 aggregates. Comparing the results 
of the two techniques for SOD1 samples can give information also for their general applicability 
to analyze metal content for other protein aggregates.  
The most inconvenient aspect of ICP-AES for this purpose, in these experiments, was 
obtaining the necessary large amount of protein (at least ~30 mg of SOD1 per sample). This is 
due to the volume of digested sample necessary to run the machine (at least 10 mL with 
minimum metal concentrations of 2.9 mg/L Cu and 1.3 mg/L Zn, as well as the extent of the 
inclusion body formation. Due to some SOD1 variants forming lower levels of inclusion bodies, 
more culture is needed. In comparison, the PAR assay required 100 fold less protein. 
 82 
 
Although the acid digestion preparation of the samples for ICP-AES was augmented in 
order to utilize the PAR assay on the WT background SOD1 mutants, the PAR assay is still ideal 
to be conducted on proteins with no ability to form aberrant disulfide bonds in chemical 
denaturant, including the pWT SOD1 mutants100. For ICP-AES is important to avoid high levels 
of salts in solution, some may cause reductions in the signal of the metal of interest if they cool 
the flame, for example high sodium can have this effect (1 g/L can cause a decrease in Cu signal 
intensity by 15%) .138,139 In terms of flexibility of sample preparation, this may be an argument in 
favour of using the PAR technique.  
ICP-AES was convenient for analyzing multiple samples. Here, it was necessary to 
analyze a large number of samples, where several mutants of SOD1 were analyzed and 
compared to each other. Having the ability to use an instrument that accommodates a program to 
analyze multiple samples in succession with minimal time between sample readings without 
extra interaction is beneficial. This is in contrast to the PAR assay, in which, taking the time to 
properly clean the cuvette used is an important factor, as residual metals may affect the next 
sample. This involved continually washing with nitric acid and thoroughly rinsing with MilliQ 
grade water between each sample. Both techniques, however, provided inconsistent results. 
4.3.4 Metallation of SOD1 Mutants 
When comparing the results of both techniques used here, there were some similarities as 
well as some differences. The inconsistency in trials was one similarity between the two 
techniques. This could have indicated either an inherent problem with the procedure itself or the 
inclusion bodies were binding very different amounts of metals seemingly at random but perhaps 
relating to the circumstances of the growth and expression. This variability is not likely arising 
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from the instrument since when the same sample was analyzed by both PAR and ICP-AES after 
acid digestion, similar results were obtained (Figure 4.7) 
 
Figure 4.7: PAR and ICP-AES metalation results of the SOD1 mutant acid digested inclusion 
body samples. A4V#1 and #2 were samples prepared from repeated culture growths. 
 
The results of both PAR and ICP-AES experiments indicate that the SOD1 IBs contain 
some metal. When assessing the possibility that metals could bind in the inclusion bodies, a 
number of factors were taken into consideration. The first was residual structure of the protein. 
As mentioned in section 1, IB’s had generally been considered amorphous34,140. More recently, 
the internal structure of inclusion bodies has been characterized in further detail. The observation 
of amyloid like structure33,34,140 as well as residual activity in some inclusions128,141 has raised 
many more questions about not only the process of IB formation, but also possible uses for IB’s. 
The presence of metals in IB samples here, suggests exploring studies to determine levels of 
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residual activity in mutant SOD1 inclusions. Since the levels of aggregation for each mutant 
have been determined, by continuing with the characterization of activity, the mutant with the 
highest activity to inclusion body yield could be identified. This may be useful for applications 
requiring an insoluble or immobilized superoxide dismutase catalyst. 
 If the binding of the metals is not regulated by chaperones or the other cellular 
components normally found in human cells, it may be reasonable to predict mismetallation in 
E.coli. As mentioned in Section 1.4.6, SOD1 normally utilizes the CCS protein for proper Cu 
metalation82,84,85. If this chaperone is not present, it is highly unlikely that the SOD1 grown in 
E.coli will reach a fully metallated state. This may affect the level of copper observed in some of 
the IB’s. However, the large amount of copper and zinc present in the media may cause metals to 
“stick” to the inclusion bodies. In regards to the metal content of inclusions in humans, there are 
no direct analyses, however, copper has been found to be elevated in the cerebrospinal fluid of 
ALS patients.142 
Finally, it is worth noting that a significant source of error for the accuracy of either 
technique is likely the determination of protein concentration. The error associated with the 
densitometric protein determination can be high if care is not taken. The differences in the 
experiments for A4V however appear to be larger than the experimental uncertainties as 
estimated from analyzing many samples; this suggests that there is likely real variation in the 
levels of metal content.  
 The study of the misfolding and aggregation of fALS-associated mutant SOD1 is still a 
very active field. The studies here support why that is, with the observation of correlations 
between the thermal stability and aggregation propensities of SOD1 variants in E.coli and 
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supporting the possibility that mutant SOD1 IB’s may bind metal. Questions still remain 
regarding how metals are bound to aggregates, as well as how much the differing aggregation 
propensities of mutants has to do with disease. It would also be interesting to investigate how the 
presence of CCS may affect SOD1 IB formation in E.coli. The results discussed here may help 
future generations with the many remaining questions regarding the aggregation of SOD1 in 
ALS, while also providing insights into IB formation for protein production and the design of 
functional insoluble biocatalysts.  
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Appendix 
Appendix 1: Normalized aggregation prediction algorithm results for various aggregation 
prediction algorithms used to analyze SOD1 mutants, from Heather Primmer127. 
 
Zyggregator Chiti-dobson Wang agar Ztox fold amyloid Pasta Tango Waltz Profile 3D
WT 0.7 0.56 0.47 0.65 0.51 0.59 0.45 0.83 0.39
A4V 0.94 0.69 0.61 0.96 0.77 0.61 1 0.83 0.41
G37R 0.41 0.39 0.24 1 0.67 0.59 0.45 0.61 0.19
G41D 0.45 0.2 0.02 0 0.54 0.59 0.45 0 0.59
G41S 0.65 0.58 0.45 0.19 0.55 0.59 0.45 0.45 1
H43R 0.5 0.26 0.15 0.09 0.51 0.59 0.45 0.35 0.39
H46R 0.6 0.41 0.27 0.29 0.52 0.59 0.45 0.41 0.2
L84V 0.8 0 0.73 0.51 0.59 0.45 0.92 0.39
G85R 0.56 0.39 0.24 0.68 0.62 0.59 0.45 0.71 0
D90A 0.91 1 1 0.85 0.53 0.59 0.45 0.88 0.41
G93A 0.68 0.55 0.48 0.78 0.6 0.6 0.45 0.83 0.2
E100G 0.98 0.75 0.76 0.64 0.51 0.61 0.45 0.95 0.59
I113T 0.78 0.39 0.24 0.72 0.21 0 0.45 0.79 0.2
L144F 0.91 0.58 0.5 0.97 0.5 0.59 0.73 1 0.6
V148G 0.58 0.35 0.26 0.62 0.62 0.59 0 0.85 0.15
V148I 0.68 0.5 0.39 0.82 0 0.59 0.43 0.9 0.6
